ArticlePDF Available

Next-generation antimicrobials: From chemical biology to first-in-class drugs

August 2015
Archives of Pharmacal Research 38(9)

DOI:10.1007/s12272-015-0645-0

Source
PubMed

License
CC BY 4.0

Authors:

Michelle Lay Teng Ang

Nanyang Technological University

The global emergence of multi-drug resistant bacteria invokes an urgent and imperative necessity for the identification of novel antimicrobials. The general lack of success in progressing novel chemical entities from target-based drug screens have prompted calls for radical and innovative approaches for drug discovery. Recent developments in chemical biology and target deconvolution strategies have revived interests in the utilization of whole-cell phenotypic screens and resulted in several success stories for the discovery and development novel drug candidates and target pathways. In this review, we present and discuss recent chemical biology approaches focusing on the discovery of novel targets and new lead molecules for the treatment of human bacterial and protozoan infections.

Content uploaded by Michelle Lay Teng Ang

Content may be subject to copyright.

Available via license: CC BY 4.0

Content may be subject to copyright.

REVIEW

Next-generation antimicrobials: from chemical biology

to ﬁrst-in-class drugs

Michelle Lay Teng Ang

•Paul Murima

•Kevin Pethe

Received: 16 April 2015 / Accepted: 29 July 2015

ÓThe Author(s) 2015. This article is published with open access at Springerlink.com

Abstract The global emergence of multi-drug resistant

bacteria invokes an urgent and imperative necessity for the

identiﬁcation of novel antimicrobials. The general lack of

success in progressing novel chemical entities from target-

based drug screens have prompted calls for radical and

innovative approaches for drug discovery. Recent devel-

opments in chemical biology and target deconvolution

strategies have revived interests in the utilization of whole-

cell phenotypic screens and resulted in several success

stories for the discovery and development novel drug

candidates and target pathways. In this review, we present

and discuss recent chemical biology approaches focusing

on the discovery of novel targets and new lead molecules

for the treatment of human bacterial and protozoan

infections.

Keywords Drug discovery Antimicrobials First-in-

class drugs Screening Lead optimization Chemical

biology

Introduction

Since the dawn of the genomics era, the main focus of drug

discovery has been on targeting cellular processes or

deﬁned enzymes that have a key role in disease patho-

genesis (Hopkins and Groom 2002; Vander Heiden 2011).

The target-centric approach enabled the testing of a speciﬁc

biological hypothesis and the rational design of drug can-

didates to modulate it. Although functional genomics has

transformed how antibacterial drug discovery is approa-

ched, very few genomics-driven compounds are currently

in clinical development. Target-based drug discovery is

overly reductionist in concept, reducing the drug–organism

relationship to inordinate drug-target interplay. This dis-

sociation from bacterial systems pharmacology is in con-

trast to the integrated network response to perturbation that

microbes are endowed with.

Prior to the introduction of biochemical screening that

emerged after sequencing of most human pathogens, drug

discovery was driven empirically by a cell-based approach,

abiding by the mantra of ‘‘selectively kill the bacteria ﬁrst

and understand why later’’. These antibiotics, such as para-

aminosalicylic acid (PAS) and pyrazinamide (PZA), were

introduced to clinical practice with limited knowledge

about the mechanism of action.

Although the ﬁeld was successful in the discovery and

development of the current antibacterial armamentarium

(Fischbach and Walsh 2009), the limited use of empiric

whole cell screening approach in recent years has con-

tributed in part to the current dearth of new antibacterials

(Sams-Dodd 2005; Fischbach and Walsh 2009; Dick and

Young 2011).

A consequential impediment of empiric cell based

screening is that the target protein remains unknown,

making lead optimization steps more time-consuming and

&Michelle Lay Teng Ang

michelle.ang@ntu.edu.sg

Kevin Pethe

kevin.pethe@ntu.edu.sg

Lee Kong Chian School of Medicine and School of

Biological Sciences, Nanyang Technological University, 30

Biopolis Street, #B2-15a, Singapore 138671, Singapore

Global Health Institute, Swiss Federal Institute of

Technology in Lausanne (EPFL), 1015 Lausanne,

Switzerland

123

Arch. Pharm. Res.

DOI 10.1007/s12272-015-0645-0

challenging (Plouffe et al. 2008; Swinney 2013). Never-

theless, progress in chemical biology and target deconvo-

lution strategies has revived high-throughput whole-cell

phenotypic screening (Terstappen et al. 2007), whilst

exploiting cutting-edge technologies to accelerate the dis-

covery and development of novel antimicrobials (Andries

et al. 2005; Makarov et al. 2009; Rottmann et al. 2010;

Pethe et al. 2013; Ling et al. 2015). This has culminated in

the discovery of several ﬁrst-in-class medicines with novel

molecular mechanism of actions (MMOA). Automation

and miniaturization of cellular screening systems enable

the collation of unprecedented amounts of data for a single

small molecule across a diverse collection of cellular

screens, thus providing insights into a compound’s possible

MMOA upon comprehensive evaluation (Plouffe et al.

2008). In fact, a recent analysis suggested phenotypic

screens to be the more successful strategy for the discovery

of ﬁrst-in-class medicines (Swinney 2013). The rational-

ization for the success of phenotype-based screens was the

unbiased identiﬁcation of the MMOA.

Given the success of phenotypic screens in delivering new

chemical entities (NCE) inhibiting virgin target space, we

herein review recent chemical biology approaches focusing

on the discovery of novel targets and new lead molecules for

the treatment of human bacterial and protozoan infections.

Chemical biology strategies for protozoan

parasites

Protozoa are a wide group of unicellular organisms that can

be found in multiple ecosystems and are often non-patho-

genic for humans. However, a small subset of protozoa has

evolved as lethal intracellular parasites posing serious global

health challenges. Among the most deadly intracellular

protozoan parasites are those of the genus Plasmodium,

Leishmania and Trypanosoma, which are collectively

responsible for millions of death every year. Due to the

emergence and spread of drug resistance (Dondorp et al.

2009; Tun et al. 2015), treatment options are often limited

with reduced efﬁcacy (Wongsrichanalai and Meshnick

2008). Drug R&D have been largely inexistent for these

three parasites until early 2000’ when initiatives from lead-

ing pharmaceutical industries, largely supported by philan-

thropic and public nonproﬁt organizations emerged as a new

business model to develop drugs for neglected diseases.

These product development partnerships (PDP) have

brought promising candidates for malaria in a record time.

Plasmodium

There are four species of Plasmodium that cause malaria in

human. Collectively, they are responsible for 584,000

deaths and more than 200 million cases every year. The

most common species are Plasmodium falciparum and

Plasmodium vivax. The discovery and development of

KAE609; an investigational drug to treat malaria is the

most notable example of an antimalarial drug resulting

from the effort of a PDP. The spiroindolone KAE609 was

discovered in a phenotypic screen designed to identify

small-molecules that rapidly clear intracellular P. falci-

parum from human red blood cells (Plouffe et al. 2008).

Owing to its high potency in the cellular assay, low toxic

liability and an early proof of efﬁcacy in infected animals

(Rottmann et al. 2010; Yeung et al. 2010), the spiroin-

dolone series was optimized to improve overall properties.

A reverse genetic approach was employed to identify the

Na(?) efﬂux ATPase PfATP4 as the molecular target of

the spiroindolone series (Rottmann et al. 2010; Spillman

et al. 2013). Having demonstrated a remarkable efﬁcacy in

a phase 2a study at low dose, the optimized clinical can-

didate KAE609 has the potential to revolutionize malaria

treatment (White et al. 2014; Held et al. 2015). The road is

still uncertain before the introduction of KAE609 to clin-

ical practice, but the program is a paradigm of how a PDP

together with international collaborations can revolutionize

the drug discovery process. Besides the discovery of

KAE609, the same phenotypic screen also screen deliver

KAE609, but also the novel class of imidazolopiperazines

(IP) (Meister et al. 2011; Derbyshire et al. 2012), which is

under clinical development (Leong et al. 2014).

A similar forward chemical genetics approach was

conducted by two independent teams to identify hundreds

of novel chemotypes active against drug resistant P. fal-

ciparum (Gamo et al. 2010; Guiguemde et al. 2010). The

release of the chemical structures in the public domain is

yet another example on how open innovation can acceler-

ate drug discovery for neglected diseases. In an elegant

reverse chemical genetics approach targeting 61 proteins

and enzymes of P. falciparum, Crowther et al. identiﬁed

the putative target of several promising hits using a thermal

shift assay (Crowther et al. 2009). Even though validation

experiments are yet to be performed to ascertain target

engagement, their preliminary results set a solid foundation

in spearheading translational research. Since the release of

the chemical structures, several lead series have been

evaluated for further evaluation (Sanz et al. 2011; Jimenez-

Diaz et al. 2014; Vaidya et al. 2014). Interestingly, the

promising dihydroisoquinolines compound (?)-SJ733

compound act through PfATP4 to mediate host clearance

of the parasite (Jimenez-Diaz et al. 2014), which is also the

target of mechanism shared with KAE609 (Spillman et al.

2013).

A most challenging subpopulation of Plasmodium to

eradicate is the liver form of the disease. Plasmodium

infect hepatocytes as sporozoites that ﬁrst undergo a phase

A. L. T. Michelle et al.

123

of maturation before emerging in the blood to cause disease

manifestations. Targeting the early exoerythrocytic form of

the parasite could be prophylactic since it would eradicate

Plasmodium before the onset of the disease. In a technical

tour de force, Meister et al. developed a high-content assay

to quantify replication of P. yeollii inside human hepato-

cytes (Meister et al. 2011). An image-based approach is

particularly well adapted for screening since only 1 % of

the hepatocytes are infected by the parasites. By screening

a collection of more than 4000 commercially available

compounds that have activity against blood stage P. fal-

ciparum, the authors identiﬁed several chemicals that kill

exoerythrocytic parasites. The most advanced drug candi-

date GNF179 provided protection against a challenge with

P. berghei sporozoite, demonstrating in vivo activity

against the early-liver stage of the disease. The putative

target for GNF179 is pfcar1, an uncharacterized protein

that is postulated to be involved in protein folding that is

assumed to be essential for the biology of both the liver and

blood stages of Plasmodium infection (Jonikas et al. 2009).

More recently, a team at AstraZeneca utilized another

high-throughput imaging assay to identify 2 more novel

classes of fast-acting antiplasmodial agents; the N-aryl-2-

aminobenzimidazoles, which targets the asexual blood

stages of P. falciparum (Ramachandran et al. 2014), and

the triaminopyrimidines (TAPs), which may potentially be

used for single-dose treatment of malaria when used in

multidrug combination therapy (Hameed et al. 2015).

Exhibiting potent and wide-spectrum antimalarial activity

against multiple life-cycle stages of P. falciparum,

DDD107498 is another optimized lead derived from a 2,

6-disubstituted quinolone-4-carboxamide scaffold previ-

ously identiﬁed from a previous phenotypic screen (Bara-

gana et al. 2015).

A key challenge in quest to eradicate malaria is the lack

of potent drugs active against exoerythrocytic Plasmodium

vivax.P. vivax is the most common form of malaria in

South-east Asia. Although less deadly than P. falciparum,

this species can survive in a dormant form as hypnozoites

for extended period of time, leading to recurrent relapse

(Wells et al. 2010). The identiﬁcation of drug candidates

active against hypnozoites is challenging due to the lack of

predictive ex vivo models amenable to large-scale pheno-

typic screens. (Wells et al. 2010). Recent technical devel-

opments bring about cautious but yet resurgent optimism

for the eventual discovery for an inherent cure for vivax

malaria, through the complete eradication of all forms of

Malaria parasites from the body. Using a low-throughput

assay designed to quantify the number of hypnozoites and

schizont forms of Plasmodium cynomolgi (a model for P.

vivax) inside rhesus hepatocytes, the drug candidate

KAI407 was identiﬁed for activity in reducing the forma-

tion of hypnozoites (Zou et al. 2014). In vivo prophylactic

efﬁcacy suggests that KAI407 may indeed represent a

radical cure for vivax malaria. In prospect, the recent

development of transgenic ﬂuorescent P. cynomolgi

(Voorberg-van der Wel et al. 2013), and of platforms that

recapitulate the hepatic stage of P. vivax (Chattopadhyay

et al. 2010; March et al. 2013) will probably be instru-

mental in the coming year to the identiﬁcation and devel-

opment of drugs targeting P. vivax hypnozoites.

Other kinetoplastids

Parasites of the genus Trypanosoma and Leishmania are

kinetoplastid protozoan parasites that cause trypanosomi-

asis and leishmaniasis, respectively. These diseases,

prevalent in tropical and subtropical countries, cause sig-

niﬁcant morbidity and mortality. No vaccines are available;

and the current chemotherapies available for these

neglected tropical diseases (NTDs) are limited with mul-

tiple shortcomings including potentially severe side effects,

lengthy drug regimens and variable efﬁcacy.

Chagas disease, caused by Trypanosoma cruzi, is the

major cause of heart failure in Latin America. The only 2

available chemotherapies are benznidazole and nifurtimox,

which have been shown to be largely ineffective and toxic,

commonly causing drug resistance (Filardi and Brener

1987; Viotti et al. 2006). Drug R&D for Chagas disease is

challenging due to the complex infection cycle of T. cruzi

that can persist for many years in infected patients as try-

pomastigotes and amastigotes. The availability of engi-

neered reporter gene expressing-parasites (Bettiol et al.

2009; Canavaci et al. 2010) have triggered the develop-

ment of phenotypic assays suitable for HTS, as well as the

establishment of new in vivo protocols (Canavaci et al.

2010; Rodriguez and Tarleton 2012) that allow faster

evaluation of experimental therapeutic options.

Automated high content microscopy approaches (Engel

et al. 2010; Moon et al. 2014) have been used to identify

new parasitic inhibitors. To mimic the intracellular life

cycle of T. cruzi for drug screening, Engel et al. developed

and validated a ﬂexible cell-based, high-throughput

96-well plate assay that could be used with a variety of

untransfected T. cruzi isolates and host cells (Engel et al.

2010). This allowed the simultaneous measurement of both

efﬁcacies against the intracellular amastigote stage and

host cell toxicity. Validation of the HTS assay enabled the

identiﬁcation of 55 hits upon screening a library of 909

bioactive compounds. Further drug testing narrowed the

list down to 17 compounds that showed at least 5-fold

selectivity between the inhibition of T. cruzi and host cell

toxicity (Engel et al. 2010). Since these conﬁrmed hits

were selected from a library of clinical drugs, they could

potentially be repurposed for T. cruzi treatment and used

for mode of action and target identiﬁcation studies. In a

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

similar vein, a team from the Institut Pasteur Korea cus-

tomized a high content image-based and HTS algorithm for

the quantiﬁcation of infection ratio and intracellular T.

cruzi amastigote in human cell line in response to drug

treatment (Moon et al. 2014). Based solely on DNA

staining and single-channel images, the algorithm precisely

segments and identiﬁes the nuclei and cytoplasm of

mammalian host cells as well as the intracellular parasites

infecting the cells to produce various statistical parameters

that can be used to assess both drug responses and com-

pound cytotoxicity (Moon et al. 2014).

The Genomics Institute of the Novartis Foundation (GNF)

has also initiated a drug discovery program for Chagas disease

using phenotypic screens that measure the inhibition of pro-

liferation of various kinetoplastid parasites to identify hits

among low molecular mass compounds (Bustamante et al.

2011). To date, GNF has screened around 700,000 small

molecules against the bloodstream form of T. brucei and the

Leishmania donovani axenic amastigotes, which yielded

around 2,000 conﬁrmed hits in total. 44 % of these hits were

also found to be active against intracellular T. cruzi

(IC50 \4lM). Several of these T. cruzi-active compounds

that possess a favorable proﬁle have been selected for medic-

inal chemistry exploration with the goal of identifying lead

scaffolds that could be further optimized. These early efforts

have resulted in the discovery of analogs with sub-nanomolar

potency against T. cruzi (Bustamante et al. 2011). These

screens have also been recently extended to a larger 1.8 million

compound library to identify T. cruzi-active compounds

(Bustamante et al. 2011). It is expected that these screening

efforts by GNF will eventually yield a single pool of anti-T.

cruzi compounds that will be further validated and chemically

optimized to yield preclinical candidates that could address this

crucial gap in drug discovery for Chagas disease.

Leishmaniasis has been ranked among the most

neglected of tropical diseases. As a group of diseases

caused by trypanosomatids from the genus, cutaneous and

mucosal leishmaniases are the predominant pathologies

produced by Leishmania infection. Several drugs are cur-

rently available to treat cutaneous leishmaniasis, but each

has limitations (Cruz et al. 2009). While target-based

screening approaches for anti-leishmanial drug discovery

has yielded little progress for a variety of reasons (Freitas-

Junior et al. 2012), the development and implementation of

HTS phenotypic assays by individual academic groups,

consortia and public–private partnerships have generated

several potential starting points for drug development.

There is a general consensus for an urgent need for more

reliable phenotypic in vitro screening that would mimic as

closely as possible the deﬁnitive host environment.

Therefore, genetically modiﬁed parasites expressing easily

detectable reporters represent promising tools for pheno-

typic screening (Reguera et al. 2014).

Yet another evident advancement in this ﬁeld is the

development and validation of a high-content, high-

throughput image-based screening assay targeting the

intracellular amastigote stage of different species of

Leishmania in infected human macrophages without the

need for a reporter gene (Siqueira-Neto et al. 2012). The

in vitro infection protocol was adapted to a 384-well-plate

format, thus enabling acquisition of a large amount of

readouts by automated confocal microscopy. This assay

has enabled the screening of up to 300,000 compounds to

obtain 350 hits (Siqueira-Neto et al. 2012; Reguera et al.

2014). Since the same study also established that only 4 %

of the hits identiﬁed by using Leishmania promastigotes

display efﬁcacy against intracellular amastigote forms

(Siqueira-Neto et al. 2012), intracellular amastigote-based

phenotypic screening is reinforced as the most suitable

approach to be developed.

An exciting approach that is midway between in vitro

cell infections and experimental infections in mice consists

of the use of ex vivo explants of Leishmania-infected

organs. Target-infected organs are harvested from ﬂuores-

cent or bioluminescent Leishmania-infected rodents for

development of ex vivo explant culture. These splenic or

lymph node ex vivo infected explants are advantageous

over in vitro systems by including the whole cellular

population involved in the host-parasite interaction: mac-

rophages, CD3 ?and CD4 ?T cells, B lymphocytes and

granulocytes; which could affect the therapeutic effect of

the tested compound. Since a single infected spleen can

yield up to four 96-well plates, the use of these ex vivo

explants will also drastically reduce the number of animals

used for screening, whilst still enabling medium-through-

put screening capabilities. Using this approach, 4,035

compounds were screened at a single-dose concentration

against luciferase-transfected L. donovani-infected ex vivo

hamster spleens, revealing more than 200 active hits

(Osorio et al. 2011). More recently, the same group has

also validated a lymph node ex vivo explant model using

the same bioluminescent reporter in a L. major strain

(Peniche et al. 2014).

Furthermore, lead compounds can be scaled up to

in vivo preclinical trials using rodent models of infection

monitoring parasite loads by means of advanced bioimag-

ing devices. The use of quick and reproducible ﬂuorescent

and bioluminescent readouts would greatly reduce the

number of animals used for these trials and allow for an

earlier stage detection of the infective process as compared

with classical methods (Reguera et al. 2014). A total of

near half million compounds have been screened for vis-

ceral leishmaniasis treatment through a series of cutting-

edge technologies combined with optimized assays (Fre-

itas-Junior et al. 2012). However, since more systemic

approaches to develop new chemical entities for

A. L. T. Michelle et al.

123

leishmaniasis have started only recently, the late discovery

process is still in its infancy.

Human African trypanosomiasis (HAT), also known as

sleeping sickness, is yet another example of a vector-

transmitted disease caused by 2 T. brucei subspecies

namely, T. b. gambiense and T. b. rhodesiense. Untreated

HAT leads to a fatal outcome, causing signiﬁcant mor-

bidity and mortality. With no vaccine available, current

chemotherapy against HAT relies on four drugs that pos-

sess several limitations and occasional severe side-effects.

Whole-cell assays in HTS format for T. brucei are rela-

tively new, with the development of luciferase and resa-

zurin-based cell viability assays a 384-well format

(Mackey et al. 2006; Sykes and Avery 2009a,b). HTS

resazurin-based assays have been recently used to screen

87,296 compounds, resulting in 6 hits from 5 new chemical

classes with activity conﬁrmed against the causative spe-

cies of HAT (Sykes et al. 2012). Being intensively used in

antimalarial drug discovery as well (Smilkstein et al. 2004;

Johnson et al. 2007; Izumiyama et al. 2009; Vossen et al.

2010), SYBR Green whole-cell assays, which are an

indirect assessment of cell number based on quantitative

detection of nuclei acids, have also been found to be

applicable to T. brucei. To aid in drug discovery efforts for

HAT, both assays were semi-automated to screen a library

of 4,000 putative kinase inhibitors (Faria et al. 2015). The

compounds with the most potent anti-trypanosomal activity

could be grouped into 13 structural clusters. Several of the

identiﬁed compounds had IC

\1lM coupled with high

selectivity toward the parasite, thus providing promising

starting points for lead optimization.

The limitation for the development of novel lead candi-

dates for kinetoplastid parasites remains in target identiﬁ-

cation. Early identiﬁcation of the candidate target and

demonstration of target engagement would indeed acce lerate

drug development by using enzymatic assays or biophysical

methods to rationally optimize drug candidates. While

efforts can be further expanded for drug discovery for these

NTDs, it is anticipated that novel drug candidates are on the

horizon for the treatment of trypanosomiasis and leishma-

niasis. On the model of P. falciparum, selection of escape

mutants followed by whole-genome sequencing is probably

the most straightforward approach to identify the target, or at

least mechanisms of resistance.

Chemical biology strategies for pathogenic

bacteria

The emergence of multi-drug resistant (MDR) bacteria

poses enormous public health issues. Despite recurrent call

for actions, efforts and investments from the public and

private sector do not match the threat posed by MDR

germs, especially by emerging gram-negative bacteria,

often referred to as superbugs. Among the most deadly

bacteria are Mycobacterium tuberculosis, the etiological

agent of human tuberculosis, and those known as the

‘‘ESKAPE’’ pathogens Enterococcus faecium,Staphylo-

coccus aureus,Klebsiella pneumoniae,Acinetobacter

baumanii,Pseudomonas aeruginosa, and Enterobacter

species that cause the lion’s share of hospital-acquired

infections (Rice 2008; Boucher et al. 2009; Rice 2010).

The global R&D pipeline remains extremely thin for

broad-spectrum antibiotics, especially for the gram-nega-

tive ESKAPE bugs (Boucher et al. 2013). Innovation in

chemical biology and target deconvolution strategies rep-

resents the most promising approach to discover novel

antimicrobials, as exempliﬁed by recent success stories for

tuberculosis.

Mycobacterium tuberculosis

Tuberculosis (TB) remains a major global health challenge,

with nearly 1.5 million TB-related deaths in 2013 alone

(WHO 2013). Underlying the endemic is the emerging

epidemic of multi-drug resistant (MDR-TB) and exten-

sively-drug resistant (XDR-TB) TB strains. With dwin-

dling treatment options for MDR and XDR-TB, one of the

pertinent key issues faced by the TB research community is

the daunting challenge of discovering and developing new

anti-TB drugs. Phenotypic screens have been used exten-

sively in the last decade to discover innovative drug can-

didates, contributing to replenish the drug pipeline.

Historically, most anti-tuberculosis drugs were identi-

ﬁed by screening candidate drugs against Mycobacterium

tuberculosis (Mtb) replicating in culture broth medium.

The exception is pyrazinamide, a sterilizing ﬁrst-line anti-

TB drug that was discovered by a bold phenotypic screen

in infected animals (Malone et al. 1952). Mode of action

was usually not understood at the time of introduction to

clinical practice. The sequencing of the Mtb genome in

1998 (Cole et al. 1998) led to the emergence of target based

drug discovery and prompted the ﬁeld to reconsider the

utility of phenotypic screens. The difﬁculty in ﬁnding tar-

gets inhibited by the compounds with whole cell activity

was central to the departure from the phenotypic screening

paradigm. Nevertheless, the landscape changed rapidly.

Improved technologies for de-orphaning phenotypic

screening hits has prompted renewed interest in pursuing

whole cell phenotypic screens for novel, constructive

sources of lead molecules/series.

The success of chemical biology for TB drug discovery

is best epitomized by the discovery of the diarylquinoline

bedaquiline (Sirturo

) (Andries et al. 2005). Bedaquiline is

the ﬁrst drug approved for the treatment of tuberculosis in

the last 40 years. The drug was identiﬁed from a corporate

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

collection screening campaign against Mycobacterium

smegmatis, a surrogate environmental, non-pathogenic

mycobacteria (Andries et al. 2005). Limited chemical

optimization of a diarylquinolone series led to bedaquiline,

a compound with exceptional potency against Mtb in vitro

and in animal models (Andries et al. 2005). Whole-genome

sequencing of spontaneous mutants resistant to bedaquiline

revealed the F

ATP synthetase as the drug target.

Despite its evolutionary conservation, bedaquiline is highly

speciﬁc for the mycobacterial complex. The inhibition of

ATP synthase leads to ATP depletion and pH homeostasis

imbalance, triggering bacterial death of both replicating

and non-replicating mycobacteria (Deckers-Hebestreit and

Altendorf 1996; Rao et al. 2001). Bedaquiline recently

underwent accelerated approval by the Food and Drug

Administration (FDA) for the treatment of MDR and XDR

TB (Cohen 2013).

Delamanid is another drug available for the treatment

MDR-TB that was granted conditional approval by the

European Medicine Agency late in 2013 (Barry 2015). Full

safety and efﬁcacy is currently being evaluated in Phase III

clinical trials. Delamanid was optimized from a series of

highly potent nitro-imidazole (Stover et al. 2000) that

inhibits mycobacterial growth by targeting multiple

essential processes, including mycolic acid synthesis and

respiration (Stover et al. 2000; Matsumoto et al. 2006;

Singh et al. 2008). PA-824, another clinical phase nitro-

imidazole drug candidate discovered by whole-cell

screening, showed the promise to shorten the time of

MDR-TB therapy when given in combination with moxi-

ﬂoxacin, pyrazinamide and/or bedaquiline (Diacon et al.

2012; Dawson et al. 2015; Tasneen et al. 2015).

Using a similar approach, ppromising drug candidates

with a novel mode of action were recently reported. Of

particular interest is a series of indolcarboxamine that

inhibits mycobacteria growth by interfering with the

function of MmpL3, a transporter of trehalose monomy-

colate that is essential for mycobacterial cell wall biosyn-

thesis (Rao et al. 2013). The optimized indolcarboxamine

drug candidate NITD-304 and NITD-349 have excellent

in vivo efﬁcacy, low toxicity and favorable pharmacoki-

netic properties in multiple species, which are properties

that support clinical development of the series for the

treatment of MDR-TB. The same team recently reported on

the discovery of yet another promising class of mycolic

acid inhibitors, the 4-hydroxy-2-pyridones (Manjunatha

et al. 2015). This novel chemical series inhibits InhA, an

essential enzyme involved in mycolic acid synthesis

(Takayama et al. 1975), which was also recently estab-

lished as the target of the natural compound pyridomycin

(Hartkoorn et al. 2012,2014). GSK has also released a set

of 177 potent non-cytotoxic hits active against Mtb using

comparable screening methodologies with the aim of

fuelling open-source early-stage drug discovery activities

(Ballell et al. 2013). The set of compounds represent a

valuable resource for the TB community to initiate lead

optimization and/or target identiﬁcation programmes.

By virtue of being a facultative intracellular bacterium

that becomes partially phenotypically drug resistant to

multiple antibacterial when hiding inside macrophages, an

attractive approach to circumvent the limitations of in vitro

culture broth media is to screen for compounds that kill

Mtb replicating inside macrophages (Kumar et al. 2010).

Indeed, the nutrients and metabolites that Mtb use to

replicate and survive in eukaryotic cells is largely predic-

tive of the in vivo situation, making it an attractive plat-

form to discover novel classes of anti-TB drugs. Several

teams have reported on the development of systems to

screen for drugs or siRNA that interfere with the survival

of Mtb inside macrophages (Christophe et al. 2010; Sun-

daramurthy et al. 2013).

Using automated confocal ﬂuorescent microscopy to

monitor the intracellular growth of GFP-expressing Mtb

H37Rv, a team from the Institut Pasteur Korea developed a

rapid phenotypic assay to screen large chemical libraries in

384-well format (Christophe et al. 2009). This phenotypic

HTS assay was the ﬁrst successful demonstration for the

feasibility of large scale screens against intracellular

mycobacteria. A series of dinitrobenzamide derivatives

(DNB) targeting the decaprenyl-phosphoribose 20epimer-

ase DprE1/DprE2, thus blocking arabinogalactan synthesis,

was discovered on this platform (Christophe et al. 2009).

Interestingly, an independent study validated further the

decaprenyl-phosphoribose 20epimerase as an attractive

drug target (Makarov et al. 2009).

The beneﬁt of the macrophage platform was further rati-

ﬁed with the discovery of the optimized imidazopyridine

amide (IPA) drug candidate Q203 (Pethe et al. 2013). Q203

is the lead drug candidate that was selected after an evalua-

tion of 477 derivatives (Kang et al. 2014). The initial dis-

covery of the anti-TB activity of the IPA series was reported

in 2011 (Moraski et al. 2011). Q203 displayed potent inhi-

bitory growth against MDR and XDR Mtb clinical isolates

in vitro by inhibiting the function of the respiratory chain, a

mechanism shared with the drug bedaquiline. Genetic and

biochemical evidences pointed to the mycobacterial cyto-

chrome bc-1 as the molecular target of the IPA series

(Abrahams et al. 2012; Pethe et al. 2013). Q203 combines

favorable properties including bactericidal activity in the

mouse model of tuberculosis at low dose and favorable

pharmacokinetic with safety proﬁles, making this compound

a promising drug candidate for tuberculosis. Intriguingly,

scientists at EPFL have identiﬁed the existing drug lanso-

prazole as an antituberculous prodrug that also targets

cytochrome bc-1 in a host cell-based high throughput screen

as well, albeit using lung ﬁbroblasts (Rybniker et al. 2015).

A. L. T. Michelle et al.

123

Recently, another large-scale compound screen in

infected macrophages revealed several interesting com-

pound series that represses the intracellular Mtb growth by

inhibiting mycobacterial cholesterol metabolism (Van-

derVen et al. 2015). Since cholesterol is a carbon source

used by Mtb in macrophages and in vivo (Rohde et al.

2012) but not in vitro, these interesting compounds series

could not have been identiﬁed by screening in classical

culture broth media, illustrating the beneﬁt of using rele-

vant models for bacterial phenotypic screen.

The added beneﬁt of screening for anti-TB drugs in

eukaryotic cells opens the possibility of identifying anti-

virulence drugs (Rybniker et al. 2014) or host-targeted

drugs that stimulate cellular pathway critical for the

maintenance of the infection (Sundaramurthy et al. 2013;

Stanley et al. 2014).

Finally, the development of a rapid screening platform

for anti-TB agents in whole animals represents a very

attractive approach. Two systems were recently devel-

oped using Mycobacterium marinum as a surrogate for

Mtb. Being a natural ﬁsh pathogen, the infection process

in zebraﬁsh larvae recapitulates many aspects of tuber-

culosis pathogenesis in humans (Swaim et al. 2006). The

zebraﬁsh larvae platform was developed in 96 well plates

and relies on automated ﬂuorometric in situ measurement

of drug efﬁcacy and toxicity. Since the entire procedure

is performed in 96 well-plates, numerous drugs can be

evaluated in parallel. The assay was validated using

known direct- and host-acting drugs (Takaki et al. 2012,

2013). More recently a comparable screening approach

was optimized in amoeba (Kicka et al. 2014). The assay

was developed in the amoeba Acanthamoeba castellanii

infected with M. marinum and validated with several

known anti-TB drugs. In principle, the system is suitable

to identify host-targeted drug candidate and compounds

interfering with virulence, which represent an advantage

compared to classical screening approaches. The perfor-

mance and beneﬁts of such platforms remain to be

determined in a large-scale compound screening

campaign.

Broad spectrum antibacterials

Gram-positive bacteria

Antibiotic resistance has become a major problem in the

treatment of Gram-positive bacterial infections, with some

of the most important gram-positive resistant organisms

including penicillin-resistant Streptococcus pneumonia and

methicillin-resistant Staphylococcus aureus (MRSA)

(Klevens et al. 2007; Arias and Murray 2009). Lately, a

number of contemporary and prominent approaches have

produced promising data in the quest for broad-spectrum

bactericidal antibiotics that could improve the clinical

outcomes for the treatment of Gram-positive bacterial

infections.

The ﬁrst notable study involved a cell-based screen of

1280 bioactive compounds from the Library of Pharma-

cologically Active Compounds (LOPAC) library against a

constitutively-expressing luciferase Mtb strain under

nutrient-deprivation conditions in order to seek inhibitors

with activity against replicating and nonreplicating Mtb

(Harbut et al. 2015). This screen culminated in the unex-

pected identiﬁcation of auranoﬁn, an orally bioavailable

FDA-approved anti-rheumatic drug, as possessing potent

bactericidal activities against a number of other clinically

important Gram-positive bacterial species. Auranoﬁn

exerts its effects through a unique mechanism involving the

inhibition of the bacterial thioredoxin reductase, a protein

essential in many Gram-positive bacteria for maintenance

of the thiol-redox balance and protection against reactive

oxygen species (Scharf et al. 1998; Uziel et al. 2004).

These ﬁndings not only suggest auranoﬁn as a viable

candidate worth repurposing for antibacterial therapy; but

its associated universal mode of action also highlight the

prospects of targeting the thioredoxin-mediated redox

cascade of Gram-positive pathogens for the development

of novel broad-spectrum antibacterials.

Another signiﬁcant breakthrough is the discovery of

novel antibiotics identiﬁed from soil bacteria recalcitrant to

grow under laboratory conditions (Ling et al. 2015). The

development of several meticulous methods to grow

uncultured organisms via in situ cultivation (Kaeberlein

et al. 2002; Nichols et al. 2010) or by using speciﬁc growth

factors (D’Onofrio et al. 2010) hold great promise to

identify novel antibiotics from natural sources. The mul-

tichannel iChip (Nichols et al. 2010) device was designed

to isolate and grow uncultured bacteria in diffusion

chambers in situ, enabling the identiﬁcation of numerous

novel soil bacteria. A large scale screen of secreted sec-

ondary metabolites from 10,000 bacterial isolates against S.

aureus led to the discovery of the novel antibiotic teix-

obactin. Teixobactin is an unusual depsipeptide that dis-

plays astounding activity against Gram-positive pathogens,

including experimentally proven in vivo efﬁcacies against

drug-resistant pathogens in a number of animal models of

infection (Ling et al. 2015). Due to its unusual mode of

action involving multiple targets and binding to a highly

conserved motif of lipid II and lipid III to inhibit pepti-

doglycan synthesis, teixobactin has been construed as a

promising therapeutic candidate with favorable pharma-

cokinetic parameters (Ling et al. 2015). Primarily, the

results of this pioneer study suggest that additional natural

compounds with similarly low susceptibility to resistance

are present in nature and may potentially be discovered

following a similar approach.

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

Table 1 Novel chemical classes identiﬁed through chemical biology screens

Disease Chemical class Lead compound(s) Chemical

structure

Identiﬁed

target

MMOA Key reference

Malaria Spiroindolones KAE609 PfATP4 Disrupts intracellular sodium homeostasis Rottmann et al. (2010)

Dihydroisoquinolines SJ733 PfATP4 Disrupts intracellular sodium homeostasis Jimenez-Diaz et al. (2014)

Imidazolopiperazines GNF179 Pfcar1 Unclear Meister et al. (2011)

Imidazopyrazines KAI407 PI(4)K Alters the intracellular distribution of

phosphatidylinositol-4-phosphate

Zou et al. (2014)

N-aryl-2-aminobenz

-imidazoles

Compound 12 in

Ramachandran et al. (2014)

NA Unclear Ramachandran et al. (2014)

Triaminopyrimidines Compound 12 in

Hameed et al. (2015)

Unclear Unclear Hameed et al. (2015)

Tuberculosis Diarylquinolones Bedaquiline F

ATP

synthetase

ATP depletion and pH homeostasis imbalance Andries et al. (2005)

Nitro-imidazoles Delamanid PA-824 Unclear Inhibits mycobacterial growth by targeting multiple

essential cellular processes, including protein,

mycolic acid synthesis and respiration

Stover et al. (2000)

Indolcarboxamines NITD-304 MmpL3 Inhibits mycobacterial cell wall synthesis Rao et al. (2013)

NITD-349

A. L. T. Michelle et al.

123

Table 1 continued

Disease Chemical class Lead compound(s) Chemical

structure

Identiﬁed

target

MMOA Key reference

4-hydroxy-2-pyridones NITD-916 InhA Inhibits mycolic acid synthesis Manjunatha et al. (2015)

Dinitrobenzamides NA NA DprE1/DprE2 Blocks arabinogalactan synthesis Christophe et al. (2009)

Imidazopyridine amides Q203 bc-1 complex Inhibits ATP synthesis Pethe et al. (2013)

Pyridomycins Pyridomycin InhA Blocks both the NADH cofactor– and lipid

substrate–binding pockets of InhA

Hartkoorn et al. (2012)

Others Depsipeptide Teixobactin Multiple targets Inhibits peptidoglycan synthesis Ling et al. (2015)

Pyridopyrimidines NA NA biotin carboxylase (BC)

complex

Inhibits fatty acid synthesis Miller et al. 2009

Pyridinemidazoles NA NA LolCDE complex Inhibits lipoprotein trafﬁcking from the inner to

the outer membrane

McLeod et al. (2015)

NA Not available

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

Gram-negative bacteria

Gram-negative bacteria are best deﬁned by their ability to

acquire and transfer drug resistance genes to other bacteria

(Hall and Collis 1998); along with their characteristic cell

envelope which comprise of a unique outer membrane of

lipoproteins, b-barrel proteins, lipopolysaccharides and

phospholipids, and an inner membrane composed of a

phospholipids bilayer. Compounding the problem of

antimicrobial-drug resistance is the immediate threat of a

reduction in the discovery and development of new

antibiotics for the treatment of Gram-negative bacteria

(Boucher et al. 2009). Accordingly, there is an urgent need

for atypical, originative and alternative modes of drug

discovery veering away from the conventional target-based

approach for drug screening.

One such notable approach was the utilization of the

Pﬁzer compound library consisting of *1.6 million com-

pounds in an unbiased whole-bacterial cell screening for

growth inhibition of a membrane-compromised, efﬂux

pump-deﬁcient strain of E. coli (tol C, imp) (Miller et al.

2009). This radical methodology focused on targeting an

antibacterial space resembling those of eukaryotic targets,

thus facilitating the identiﬁcation of a series of antibacterial

pyridopyrimidines derived from a protein kinase inhibitor

pharmacophore. These compounds were later found to

possess a previously undescribed MMOA for antibacterial

activity by targeting the ATP-binding site of biotin car-

boxylase (BC), which catalyzes the ﬁrst enzymatic step of

fatty acid biosynthesis (Cronan and Waldrop 2002).

Remarkably, these BC inhibitors also exhibited outstanding

potency against clinical isolates of fastidious Gram-nega-

tive pathogens including H. inﬂuenza and M. catarrhalis;

causative agent of many respiratory tract infections.

Despite the structural similarities of the BC active site to

those of eukaryotic protein kinases, inhibitor binding to the

BC ATP-binding site was found to be disparate from the

protein kinase-binding mode with the inhibitors, displaying

selectivity for bacterial BC. The implications behind the

identiﬁcation of antibacterials derived from a protein

kinase inhibitor pharmacophore suggest that the huge array

of eukaryotic inhibitors present in these pharmaceutical

libraries could be mined for their activity against struc-

turally related bacterial targets such as protein kinases

involved in cell–cell signaling lipopolysaccharide sugar

kinases involved in Gram-negative cell wall formation

(Miller et al. 2009).

In a similar manner, the AstraZeneca compound col-

lection (*1.2 million compounds) was screened in

384-well plate format against a permeabilized E. coli strain

(W3110 DwaaP) (McLeod et al. 2015). The shortened

lipopolysaccharide chain in this modiﬁed strain increased

membrane permeability to small molecules and warranted

the discovery of novel pyridinemidazole compounds that

inhibited lipoprotein trafﬁcking from the inner to the outer

membrane. Subsequent studies via resistance mutation

mapping and biochemical transport assays further demon-

strated the inhibition of function of the lipoprotein-releas-

ing system transmembrane proteins (LolCDE complex) via

these compounds. Being the ﬁrst reported inhibitors of the

LolCDE complex, this novel compound class not only

displayed a unique and speciﬁc mechanism of inhibition

for Gram-negative bacteria, but the identiﬁcation of their

associated novel drug target suggest further exploitation of

the outer membrane lipoprotein transport pathway as a

target for antimicrobial therapy.

Although phenotype-based screens have expanded the

repertoire of new potential drug candidates, one of the

biggest impediments is unraveling the relationships

between the phenotype(s) caused by biologically active

small molecules and their respective mechanisms (Burdine

and Kodadek 2004). Moreover, due to the poor predictive

value of conventional in vitro culture conditions used to

analyze drug candidates (Garber 1960; Brown et al. 2008;

Brinster et al. 2009; Pethe et al. 2010), it is necessary to

innovate alternative means to characterize the MMOA of

biologically active molecules. A more unconventional

approach has been established to identify inhibitors of

E. coli grown under nutrient limitation. Employing meta-

bolomics, the authors demonstrated the promise of

metabolite suppression proﬁling as a novel method for

assigning a possible mode of action for metabolic inhibi-

tors that are frequently identiﬁed in phenotypic-based

screens (Zlitni et al. 2013). This inventive strategy led to

the discovery of novel inhibitors of glycine and biotin

biosynthetic pathways in E. coli and outlined a novel

platform for the identiﬁcation of small-molecule inhibitors

of essential metabolic pathways that would be potentially

applicable and easily adapted for most bacteria.

Nonreplicating and metabolically quiescent bacteria are

causal for latent infections and relapses following ‘‘steril-

izing’’ chemotherapy (Manina et al. 2015). Actively

shifting the characteristic metabolic ﬂux of drug-tolerant

non-growing but metabolically active (NGMA) microbes

toward an actively growing state offers a fresh prospect to

control such populations. The notion of metabolic modu-

lation to enhance the efﬁcacy of current antibiotics pro-

vides key insights into the Achilles’ heel of persistent cells

(Murima et al. 2014). This was recently demonstrated by

Kim et al. with the unprecedented approach of screening a

compound library against persistent E. coli in combination

with ampicillin in a bid to identify speciﬁc killers of bac-

terial persisters (Kim et al. 2011). A small polycyclic

molecule C10 was shown to sensitize bacterial persisters to

ampicillin killing. Although the detailed mode of action for

C10 remains undeciphered, such rudimentary yet

A. L. T. Michelle et al.

123

elucidative studies capitalizing on the use of single-

chemical supplementation could be applied on a universal

basis to other bacterial systems to discover inhibitors tar-

geting NGMAs (Wakamoto et al. 2013). Other potential

metabolic strategies for eliminating persister cells include

collapsing the proton motive force (Rao et al. 2008; Allison

et al. 2011; Farha et al. 2013; Peng et al. 2015), dissipating

intracellular nutrient storage in mycobacteria (Baek et al.

2011), or inducing reactive oxygen species potency of

bactericidal antibiotics (Kohanski et al. 2007).

Future prospects for chemical biology screens

To support the discovery of novel antimicrobials, it is

heartening to observe how public and private initiatives

have collaborated, thereupon allowing researchers to gain

access to vast collections of bioactive compounds for drug

screens. This avenue has provided further motivation for

more researchers to concert towards the identiﬁcation of

new leads, expanding efforts in the drug discovery sector.

Several of the chemical biology approaches discussed in

this review have proven to be quintessential for detecting

small-molecules with optimal selective indexes for speci-

ﬁed pathogens that usually warrant favorable results in a

preclinical model of the disease; avoiding the nuances

encountered in target-based screenings associated with

poor permeability or degradation into inactive metabolites

(Reguera et al. 2014).

Indeed, chemical biology screens have proven to be

effective for the discovery of antimicrobials, as evidenced by

the discovery of a number of potential and validated ﬁrst-in-

class drugs associated with novel drug targets/pathways

emerging from these screens. In terms of drug discovery for

infectious diseases, chemical biology screens appear to have

gained the most traction and advancements in the ﬁelds of

malaria and Mtb likely due to the motivation behind relevant

interest groups, but have also proven to be applicable to other

human pathogens as well (Table 1). Furthermore, many of

the concepts behind chemical biology approaches discussed

in this review have the potential to be adapted to other human

pathogens with some prudent remodeling. Due to the limited

chemical diversity in screening libraries (Payne et al. 2007),

it is also plausible to widen the scope of these screens to

include metabolism curated libraries and natural products,

which have shown potential in pilot studies (Miller et al.

2009; Ling et al. 2015). Additionally, chemical biology

screens have advanced by quantum leaps in terms of tech-

nology, having progressed from simplistic in vitro whole cell

screens to the incorporation of reporter genes for biolumi-

nescent, ﬂuorescent or enzymatic measurements via HTS

platforms, and more recently, to bioimaging readouts in

ex vivo explants. Ultimately, the development of large-scale

in vivo chemical biology screening platform, with cutting

edge imaging and target deconvolution strategies, certainly

has the potential to accelerate even further antimicrobial

drug discovery.

Acknowledgments This work was supported by a start-up grant

from the Lee Kong Chian School of Medicine, Nanyang Techno-

logical University.

Compliance with ethical standards

Conﬂict of Interest The authors declare no conﬂict of interest with

any person or any organization.

Open Access This article is distributed under the terms of the

Creative Commons Attribution 4.0 International License (http://crea

tivecommons.org/licenses/by/4.0/), which permits unrestricted use,

distribution, and reproduction in any medium, provided you give

appropriate credit to the original author(s) and the source, provide a

link to the Creative Commons license, and indicate if changes were

made.

References

Abrahams, K.A., J.A. Cox, V.L. Spivey, N.J. Loman, M.J. Pallen, C.

Constantinidou, R. Fernandez, C. Alemparte, M.J. Remuinan, D.

Barros, L. Ballell, and G.S. Besra. 2012. Identiﬁcation of novel

imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis

QcrB. PLoS ONE 7: e52951.

Allison, K.R., M.P. Brynildsen, and J.J. Collins. 2011. Metabolite-

enabled eradication of bacterial persisters by aminoglycosides.

Nature 473: 216–220.

Andries, K., P. Verhasselt, J. Guillemont, H.W. Go

¨hlmann, J.M.

Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E.

Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E.

Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A

diarylquinoline drug active on the ATP synthase of Mycobac-

terium tuberculosis.Science 307: 223–227.

Arias, C.A., and B.E. Murray. 2009. Antibiotic-resistant bugs in the

21st century–a clinical super-challenge. New England Journal of

Medicine 360: 439–443.

Baek, S.H., A.H. Li, and C.M. Sassetti. 2011. Metabolic regulation of

mycobacterial growth and antibiotic sensitivity. PLoS Biology 9:

e1001065.

Ballell, L., R.H. Bates, R.J. Young, D. Alvarez-Gomez, E. Alvarez-

Ruiz, V. Barroso, D. Blanco, B. Crespo, J. Escribano, R.

Gonza

´lez, S. Lozano, S. Huss, A. Santos-Villarejo, J.J. Martı

´n-

Plaza, A. Mendoza, M.J. Rebollo-Lopez, M. Remuin

˜an-Blanco,

J.L. Lavandera, E. Pe

´rez-Herran, F.J. Gamo-Benito, J.F. Garcı

´a-

Bustos, D. Barros, J.P. Castro, and N. Cammack. 2013. Fueling

open-source drug discovery: 177 Small-molecule leads against

tuberculosis. ChemMedChem 8: 313–321.

Baragana, B., I. Hallyburton, M.C. Lee, N.R. Norcross, R. Grimaldi,

T.D. Otto, W.R. Proto, A.M. Blagborough, S. Meister, G.

Wirjanata, A. Ruecker, L.M. Upton, T.S. Abraham, M.J.

Almeida, A. Pradhan, A. Porzelle, M.S. Martinez, J.M. Bolscher,

A. Woodland, S. Norval, F. Zuccotto, J. Thomas, F. Simeons, L.

Stojanovski, M. Osuna-Cabello, P.M. Brock, T.S. Churcher,

K.A. Sala, S.E. Zakutansky, M.B. Jimenez-Diaz, L.M. Sanz, J.

Riley, R. Basak, M. Campbell, V.M. Avery, R.W. Sauerwein,

K.J. Dechering, R. Noviyanti, B. Campo, J.A. Frearson, I.

Angulo-Barturen, S. Ferrer-Bazaga, F.J. Gamo, P.G. Wyatt, D.

Leroy, P. Siegl, M.J. Delves, D.E. Kyle, S. Wittlin, J. Marfurt,

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

R.N. Price, R.E. Sinden, E.A. Winzeler, S.A. Charman, L.

Bebrevska, D.W. Gray, S. Campbell, A.H. Fairlamb, P.A. Willis,

J.C. Rayner, D.A. Fidock, K.D. Read, and I.H. Gilbert. 2015. A

novel multiple-stage antimalarial agent that inhibits protein

synthesis. Nature 522: 315–320.

Barry 3rd, C.E. 2015. Timing is everything for compassionate use of

delamanid. Nature Medicine 21: 211.

Bettiol, E., M. Samanovic, A.S. Murkin, J. Raper, F. Buckner, and A.

Rodriguez. 2009. Identiﬁcation of three classes of heteroaro-

matic compounds with activity against intracellular Try-

panosoma cruzi by chemical library screening. PLOS

Neglected Tropical Diseases 3: e384.

Boucher, H.W., G.H. Talbot, D.K. Benjamin Jr, J. Bradley, R.J.

Guidos, R.N. Jones, B.E. Murray, R.A. Bonomo, D. Gilbert, and

Infectious Diseases Society of A. 2013. 10 9‘20 Progress–

development of new drugs active against gram-negative bacilli:

An update from the Infectious Diseases Society of America.

Clinical Infectious Diseases 56: 1685–1694.

Boucher, H.W., G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert,

L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs,

no drugs: no ESKAPE! An update from the Infectious Diseases

Society of America. Clinical Infectious Diseases 48: 1–12.

Brinster, S., G. Lamberet, B. Staels, P. Trieu-Cuot, A. Gruss, and C.

Poyart. 2009. Type II fatty acid synthesis is not a suitable

antibiotic target for Gram-positive pathogens. Nature 458:

83–86.

Brown, S.A., K.L. Palmer, and M. Whiteley. 2008. Revisiting the host

as a growth medium. Nature Reviews Microbiology 6: 657–666.

Burdine, L., and T. Kodadek. 2004. Target identiﬁcation in chemical

genetics: The (often) missing link. Chemistry & Biology 11:

593–597.

Bustamante, J.M., H.J. Park, R.L. Tarleton, and The Chagas Drug

Discovery Consortium. 2011. Report of the 2nd Chagas Drug

Discovery Consortium meeting, held on 3 November 2010;

Atlanta GA, USA. Expert Opinion on Drug Discovery 6:

965–973.

Canavaci, A.M., J.M. Bustamante, A.M. Padilla, C.M. Perez Brandan,

L.J. Simpson, D. Xu, C.L. Boehlke, and R.L. Tarleton. 2010.

In vitro and in vivo high-throughput assays for the testing of

anti-Trypanosoma cruzi compounds. PLOS Neglected Tropical

Diseases 4: e740.

Chattopadhyay, R., S. Velmurugan, C. Chakiath, L. Andrews Donkor,

W. Milhous, J.W. Barnwell, W.E. Collins, and S.L. Hoffman.

2010. Establishment of an in vitro assay for assessing the effects

of drugs on the liver stages of Plasmodium vivax malaria. PLoS

ONE 5: e14275.

Christophe, T., F. Ewann, H.K. Jeon, J. Cechetto, and P. Brodin.

2010. High-content imaging of Mycobacterium tuberculosis-

infected macrophages: An in vitro model for tuberculosis drug

discovery. Future Medicinal Chemistry 2: 1283–1293.

Christophe, T., M. Jackson, H.K. Jeon, D. Fenistein, M. Contreras-

Dominguez, J. Kim, A. Genovesio, J.P. Carralot, F. Ewann, E.H.

Kim, S.Y. Lee, S. Kang, M.J. Seo, E.J. Park, H. Skovierova

´,H.

Pham, G. Riccardi, J.Y. Nam, L. Marsollier, M. Kempf, M.L.

Joly-Guillou, T. Oh, W.K. Shin, Z. No, U. Nehrbass, R. Brosch,

S.T. Cole, and P. Brodin. 2009. High content screening identiﬁes

decaprenyl-phosphoribose 20epimerase as a target for intracel-

lular antimycobacterial inhibitors. PLoS Pathogens 5: e1000645.

Cohen, J. 2013. Infectious disease. Approval of novel TB drug

celebrated–with restraint. Science 339: 130.

Cole, S.T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris,

S.V. Gordon, K. Eiglmeier, S. Gas, C.E. Barry, F. Tekaia, K.

Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R.

Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S.

Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule,

L. Murphy, K. Oliver, J. Osborne, M.A. Quail, M.A.

Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R.

Squares, S. Squares, J.E. Sulston, K. Taylor, S. Whitehead, and

B.G. Barrell. 1998. Deciphering the biology of Mycobacterium

tuberculosis from the complete genome sequence. Nature 393:

537–544.

Cronan Jr, J.E., and G.L. Waldrop. 2002. Multi-subunit acetyl-CoA

carboxylases. Progress in Lipid Research 41: 407–435.

Crowther, G.J., A.J. Napuli, A.P. Thomas, D.J. Chung, K.V. Kovzun,

D.J. Leibly, L.J. Castaneda, J. Bhandari, C.J. Damman, R. Hui,

W.G. Hol, F.S. Buckner, C.L. Verlinde, Z. Zhang, E. Fan, and

W.C. van Voorhis. 2009. Buffer optimization of thermal melt

assays of Plasmodium proteins for detection of small-molecule

ligands. Journal of Biomolecular Screening 14: 700–707.

Cruz, A.K., J.S. de Toledo, M. Falade, M.C. Terrao, S. Kamchon-

wongpaisan, D.E. Kyle, and C. Uthaipibull. 2009. Current

treatment and drug discovery against Leishmania spp. and

Plasmodium spp.: A review. Current Drug Targets 10: 178–192.

D’Onofrio, A., J.M. Crawford, E.J. Stewart, K. Witt, E. Gavrish, S.

Epstein, J. Clardy, and K. Lewis. 2010. Siderophores from

neighboring organisms promote the growth of uncultured

bacteria. Chemistry & Biology 17: 254–264.

Dawson, R., A.H. Diacon, D. Everitt, C. van Niekerk, P.R. Donald,

D.A. Burger, R. Schall, M. Spigelman, A. Conradie, K.

Eisenach, A. Venter, P. Ive, L. Page-Shipp, E. Variava, K.

Reither, N.E. Ntinginya, A. Pym, F. von Groote-Bidlingmaier,

and C.M. Mendel. 2015. Efﬁciency and safety of the combina-

tion of moxiﬂoxacin, pretomanid (PA-824), and pyrazinamide

during the ﬁrst 8 weeks of antituberculosis treatment: A phase

2b, open-label, partly randomised trial in patients with drug-

susceptible or drug-resistant pulmonary tuberculosis. Lancet

385: 1738–1747.

Deckers-Hebestreit, G., and K. Altendorf. 1996. The F0F1-type ATP

synthases of bacteria: Structure and function of the F0 complex.

Annual Review of Microbiology 50: 791–824.

Derbyshire, E.R., M. Prudencio, M.M. Mota, and J. Clardy. 2012.

Liver-stage malaria parasites vulnerable to diverse chemical

scaffolds. Proceedings of the National Academy of Sciences USA

109: 8511–8516.

Diacon, A.H., R. Dawson, F. von Groote-Bidlingmaier, G. Symons,

A. Venter, P.R. Donald, C. van Niekerk, D. Everitt, H. Winter, P.

Becker, C.M. Mendel, and M.K. Spigelman. 2012. 14-day

bactericidal activity of PA-824, bedaquiline, pyrazinamide, and

moxiﬂoxacin combinations: A randomised trial. Lancet 380:

986–993.

Dick, T., and D. Young. 2011. How antibacterials really work: Impact

on drug discovery. Future Microbiology 6: 603–604.

Dondorp, A.M., F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M.

Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K.

Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S.

An, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindegardh, D.

Socheat, and N.J. White. 2009. Artemisinin resistance in

Plasmodium falciparum malaria. New England Journal of

Medicine 361: 455–467.

Engel, J.C., K.K. Ang, S. Chen, M.R. Arkin, J.H. McKerrow, and P.S.

Doyle. 2010. Image-based high-throughput drug screening

targeting the intracellular stage of Trypanosoma cruzi, the agent

of Chagas’ disease. Antimicrobial Agents and Chemotherapy 54:

3326–3334.

Farha, M.A., C.P. Verschoor, D. Bowdish, and E.D. Brown. 2013.

Collapsing the proton motive force to identify synergistic

combinations against Staphylococcus aureus.Chemistry &

Biology 20: 1168–1178.

Faria, J., C.B. Moraes, R. Song, B.S. Pascoalino, N. Lee, J.L.

Siqueira-Neto, D.J. Cruz, T. Parkinson, J.R. Ioset, A. Cordeiro-

da-Silva, and L.H. Freitas-Junior. 2015. Drug discovery for

human african trypanosomiasis: Identiﬁcation of novel scaffolds

A. L. T. Michelle et al.

123

by the newly developed HTS SYBR green assay for Try-

panosoma brucei.Journal of Biomolecular Screening 20: 70–81.

Filardi, L.S., and Z. Brener. 1987. Susceptibility and natural

resistance of Trypanosoma cruzi strains to drugs used clinically

in Chagas disease. Transactions of the Royal Society of Tropical

Medicine and Hygiene 81: 755–759.

Fischbach, M.A., and C.T. Walsh. 2009. Antibiotics for emerging

pathogens. Science 325: 1089–1093.

Freitas-Junior, L.H., E. Chatelain, H.A. Kim, and J.L. Siqueira-Neto.

2012. Visceral leishmaniasis treatment: What do we have, what

do we need and how to deliver it? Int J Parasitol Drugs Drug

Resist 2: 11–19.

Gamo, F.J., L.M. Sanz, J. Vidal, C. de Cozar, E. Alvarez, J.L.

Lavandera, D.E. Vanderwall, D.V. Green, V. Kumar, S. Hasan,

J.R. Brown, C.E. Peishoff, L.R. Cardon, and J.F. Garcia-Bustos.

2010. Thousands of chemical starting points for antimalarial lead

identiﬁcation. Nature 465: 305–310.

Garber, E.D. 1960. The host as a growth medium. Annals of the New

York Academy of Sciences 88: 1187–1194.

Guiguemde, W.A., A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther,

P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B.

Jime

´nez-Dı

´az, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J.

Gut, E.R. Sharlow, I. Bathurst, F. El Mazouni, J.W. Fowble, I.

Forquer, P.L. McGinley, S. Castro, I. Angulo-Barturen, S.

Ferrer, P.J. Rosenthal, J.L. Derisi, D.J. Sullivan, J.S. Lazo, D.S.

Roos, M.K. Riscoe, M.A. Phillips, P.K. Rathod, W.C. Van

Voorhis, V.M. Avery, and R.K. Guy. 2010. Chemical genetics of

Plasmodium falciparum.Nature 465: 311–315.

Hall, R.M., and C.M. Collis. 1998. Antibiotic resistance in gram-

negative bacteria: The role of gene cassettes and integrons. Drug

Resistance Updates 1: 109–119.

Hameed, P.S., S. Solapure, V. Patil, P.P. Henrich, P.A. Magistrado, S.

Bharath, K. Murugan, P. Viswanath, J. Puttur, A. Srivastava, E.

Bellale, V. Panduga, G. Shanbag, D. Awasthy, S. Landge, S.

Morayya, K. Koushik, R. Saralaya, A. Raichurkar, N. Rautela,

N. Roy Choudhury, A. Ambady, R. Nandishaiah, J. Reddy, K.R.

Prabhakar, S. Menasinakai, S. Rudrapatna, M. Chatterji, M.B.

Jimenez-Diaz, M.S. Martinez, L.M. Sanz, O. Coburn-Flynn,

D.A. Fidock, A.K. Lukens, D.F. Wirth, B. Bandodkar, K.

Mukherjee, R.E. McLaughlin, D. Waterson, L. Rosenbrier-

Ribeiro, K. Hickling, V. Balasubramanian, P. Warner, V.

Hosagrahara, A. Dudley, P.S. Iyer, S. Narayanan, S. Kavanagh,

and V.K. Sambandamurthy. 2015. Triaminopyrimidine is a fast-

killing and long-acting antimalarial clinical candidate. Nature

Communications 6: 6715.

Harbut, M.B., C. Vilcheze, X. Luo, M.E. Hensler, H. Guo, B. Yang,

A.K. Chatterjee, V. Nizet, W.R. Jacobs Jr, P.G. Schultz, and F.

Wang. 2015. Auranoﬁn exerts broad-spectrum bactericidal

activities by targeting thiol-redox homeostasis. Proceedings of

the National Academy of Sciences USA 112: 4453–4458.

Hartkoorn, R.C., F. Pojer, J.A. Read, H. Gingell, J. Neres, O.P.

Horlacher, K.H. Altmann, and S.T. Cole. 2014. Pyridomycin

bridges the NADH- and substrate-binding pockets of the enoyl

reductase InhA. Nature Chemical Biology 10: 96–98.

Hartkoorn, R.C., C. Sala, J. Neres, F. Pojer, S. Magnet, R. Mukherjee,

S. Uplekar, S. Boy-Rottger, K.H. Altmann, and S.T. Cole. 2012.

Towards a new tuberculosis drug: Pyridomycin—nature’s isoni-

azid. EMBO Molecular Medicine 4: 1032–1042.

Held, J., S. Jeyaraj, and A. Kreidenweiss. 2015. Antimalarial

compounds in Phase II clinical development. Expert Opinion

on Investigational Drugs 24: 363–382.

Hopkins, A.L., and C.R. Groom. 2002. The druggable genome.

Nature Reviews Drug Discovery 1: 727–730.

Izumiyama, S., M. Omura, T. Takasaki, H. Ohmae, and H. Asahi.

2009. Plasmodium falciparum: Development and validation of a

measure of intraerythrocytic growth using SYBR Green I in a

ﬂow cytometer. Experimental Parasitology 121: 144–150.

Jimenez-Diaz, M.B., D. Ebert, Y. Salinas, A. Pradhan, A.M. Lehane,

M.E. Myrand-Lapierre, K.G. O’Loughlin, D.M. Shackleford, M.

Justino de Almeida, A.K. Carrillo, J.A. Clark, A.S. Dennis, J.

Diep, X. Deng, S. Duffy, A.N. Endsley, G. Fedewa, W.A.

Guiguemde, M.G. Gomez, G. Holbrook, J. Horst, C.C. Kim, J.

Liu, M.C. Lee, A. Matheny, M.S. Martinez, G. Miller, A.

Rodriguez-Alejandre, L. Sanz, M. Sigal, N.J. Spillman, P.D.

Stein, Z. Wang, F. Zhu, D. Waterson, S. Knapp, A. Shelat, V.M.

Avery, D.A. Fidock, F.J. Gamo, S.A. Charman, J.C. Mirsalis, H.

Ma, S. Ferrer, K. Kirk, I. Angulo-Barturen, D.E. Kyle, J.L.

DeRisi, D.M. Floyd, and R.K. Guy. 2014. (?)-SJ733, a clinical

candidate for malaria that acts through ATP4 to induce rapid

host-mediated clearance of Plasmodium. Proceedings of the

National Academy of Sciences USA 111: E5455–E5462.

Johnson, J.D., R.A. Dennull, L. Gerena, M. Lopez-Sanchez, N.E.

Roncal, and N.C. Waters. 2007. Assessment and continued

validation of the malaria SYBR green I-based ﬂuorescence assay

for use in malaria drug screening. Antimicrobial Agents and

Chemotherapy 51: 1926–1933.

Jonikas, M.C., S.R. Collins, V. Denic, E. Oh, E.M. Quan, V. Schmid,

J. Weibezahn, B. Schwappach, P. Walter, J.S. Weissman, and M.

Schuldiner. 2009. Comprehensive characterization of genes

required for protein folding in the endoplasmic reticulum.

Science 323: 1693–1697.

Kaeberlein, T., K. Lewis, and S.S. Epstein. 2002. Isolating ‘‘uncul-

tivable’’ microorganisms in pure culture in a simulated natural

environment. Science 296: 1127–1129.

Kang, S., R.Y. Kim, M.J. Seo, S. Lee, Y.M. Kim, M. Seo,J.J. Seo, Y. Ko,

I. Choi, J. Jang, J. Nam, S. Park, H. Kang, H.J. Kim, J. Kim, S. Ahn,

K. Pethe, K. Nam, and Z. No. 2014. Lead optimization of a novel

series of imidazo[1,2-a]pyridine amides leading to a clinical

candidate (Q203) as a multi- and extensively-drug-resistant anti-

tuberculosis agent. Journal ofMedicinal Chemistry 57: 5293–5305.

Kicka, S., V. Troﬁmov, C. Harrison, H. Ouertatani-Sakouhi, J.

McKinney, L. Scapozza, H. Hilbi, P. Cosson, and T. Soldati.

2014. Establishment and validation of whole-cell based ﬂuores-

cence assays to identify anti-mycobacterial compounds using the

Acanthamoeba castellanii-Mycobacterium marinum host-patho-

gen system. PLoS ONE 9: e87834.

Kim, J.S., P. Heo, T.J. Yang, K.S. Lee, D.H. Cho, B.T. Kim, J.H. Suh,

H.J. Lim, D. Shin, S.K. Kim, and D.H. Kweon. 2011. Selective

killing of bacterial persisters by a single chemical compound

without affecting normal antibiotic-sensitive cells. Antimicrobial

Agents and Chemotherapy 55: 5380–5383.

Klevens, R.M., M.A. Morrison, J. Nadle, S. Petit, K. Gershman, S.

Ray, L.H. Harrison, R. Lynﬁeld, G. Dumyati, J.M. Townes, A.S.

Craig, E.R. Zell, G.E. Fosheim, L.K. McDougal, R.B. Carey,

S.K. Fridkin, and Active Bacterial Core surveillance MI. 2007.

Invasive methicillin-resistant Staphylococcus aureus infections

in the United States. JAMA 298: 1763–1771.

Kohanski, M.A., D.J. Dwyer, B. Hayete, C.A. Lawrence, and J.J.

Collins. 2007. A common mechanism of cellular death induced

by bactericidal antibiotics. Cell 130: 797–810.

Kumar, D., L. Nath, M.A. Kamal, A. Varshney, A. Jain, S. Singh, and

K.V. Rao. 2010. Genome-wide analysis of the host intracellular

network that regulates survival of Mycobacterium tuberculosis.

Cell 140: 731–743.

Leong, F.J., R. Zhao, S. Zeng, B. Magnusson, T.T. Diagana, and P.

Pertel. 2014. A ﬁrst-in-human randomized, double-blind,

placebo-controlled, single- and multiple-ascending oral dose

study of novel Imidazolopiperazine KAF156 to assess its safety,

tolerability, and pharmacokinetics in healthy adult volunteers.

Antimicrobial Agents and Chemotherapy 58: 6437–6443.

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

Ling, L.L., T. Schneider, A.J. Peoples, A.L. Spoering, I. Engels, B.P.

Conlon, A. Mueller, T.F. Schaberle, DE Hughes, S. Epstein, M.

Jones, L. Lazarides, V.A. Steadman, Cohen, C.R. Felix, K.A.

Fetterman, W.P. Millett, A.G. Nitti, A.M. Zullo, C. Chen, and K.

Lewis. 2015. A new antibiotic kills pathogens without detectable

resistance. Nature 517: 455–459.

Mackey, Z.B., A.M. Baca, J.P. Mallari, B. Apsel, A. Shelat, E.J.

Hansell, P.K. Chiang, B. Wolff, K.R. Guy, J. Williams, and J.H.

McKerrow. 2006. Discovery of trypanocidal compounds by

whole cell HTS of Trypanosoma brucei.Chemical Biology &

Drug Design 67: 355–363.

Makarov, V., G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B.

Saint-Joanis, N. Dhar, M.R. Pasca, S. Buroni, A.P. Lucarelli, A.

Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova,

J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D. McKin-

ney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J.

Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S.

Gaonkar, R.K. Shandil, V. Balasubramanian, T. Balganesh, S.

Tyagi, J. Grosset, G. Riccardi, and S.T. Cole. 2009. Benzoth-

iazinones kill Mycobacterium tuberculosis by blocking arabinan

synthesis. Science 324: 801–804.

Malone, L., A. Schurr, H. Lindh, K.D. Mc, J.S. Kiser, and J.H.

Williams. 1952. The effect of pyrazinamide (aldinamide) on

experimental tuberculosis in mice. American Review of Tuber-

culosis 65: 511–518.

Manina, G., N. Dhar, and J.D. McKinney. 2015. Stress and host

immunity amplify Mycobacterium tuberculosis phenotypic

heterogeneity and induce nongrowing metabolically active

forms. Cell Host & Microbe 17: 32–46.

Manjunatha, U.H., S.P. Rao, R.R. Kondreddi, C.G. Noble, L.R. Camacho,

B.H.Tan,S.H.Ng,P.S.Ng,N.L.Miia,S.B.Lakshminarayana,M.

Herve, S.W. Barnes, W. Yu, K. Kuhen, F. Blasco, D. Beer, J.R.

Walker, P.J. Tonge, R. Glynne, P.W. Smith, and T.T. Diagana. 2015.

Direct inhibitors of InhA are active against Mycobacterium tuber-

culosis.Science translational medicine 7: 269ra263.

March, S., S. Ng, S. Velmurugan, A. Galstian, J. Shan, D.J. Logan,

A.E. Carpenter, D. Thomas, B.K. Sim, M.M. Mota, S.L.

Hoffman, and S.N. Bhatia. 2013. A microscale human liver

platform that supports the hepatic stages of Plasmodium

falciparum and vivax. Cell Host & Microbe 14: 104–115.

Matsumoto, M., H. Hashizume, T. Tomishige, M. Kawasaki, H.

Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu. 2006.

OPC-67683, a nitro-dihydro-imidazooxazole derivative with

promising action against tuberculosis in vitro and in mice. PLoS

Medicine 3: e466.

McLeod, S.M., P.R. Fleming, K. MacCormack, R.E. McLaughlin,

J.D. Whiteaker, S.I. Narita, M. Mori, H. Tokuda, and A.A.

Miller. 2015. Small molecule inhibitors of Gram-negative

lipoprotein trafﬁcking discovered by phenotypic screening.

Journal of Bacteriology 197: 1075–1082.

Meister, S., D.M. Plouffe, K.L. Kuhen, G.M. Bonamy, T. Wu, S.W.

Barnes, S.E. Bopp, R. Borboa, A.T. Bright, J. Che, S. Cohen,

N.V. Dharia, K. Gagaring, M. Gettayacamin, P. Gordon, T.

Groessl, N. Kato, M.C. Lee, C.W. McNamara, D.A. Fidock, A.

Nagle, T.G. Nam, W. Richmond, J. Roland, M. Rottmann, B.

Zhou, P. Froissard, R.J. Glynne, D. Mazier, J. Sattabongkot, P.G.

Schultz, T. Tuntland, J.R. Walker, Y. Zhou, A. Chatterjee, T.T.

Diagana, and E.A. Winzeler. 2011. Imaging of Plasmodium liver

stages to drive next-generation antimalarial drug discovery.

Science 334: 1372–1377.

Miller, J.R., S. Dunham, I. Mochalkin, C. Banotai, M. Bowman, S.

Buist, B. Dunkle, D. Hanna, H.J. Harwood, M.D. Huband, A.

Karnovsky, M. Kuhn, C. Limberakis, J.Y. Liu, S. Mehrens, W.T.

Mueller, L. Narasimhan, A. Ogden, J. Ohren, J.V. Prasad, J.A.

Shelly, L. Skerlos, M. Sulavik, V.H. Thomas, S. VanderRoest, L.

Wang, Z. Wang, A. Whitton, T. Zhu, and C.K. Stover. 2009. A

class of selective antibacterials derived from a protein kinase

inhibitor pharmacophore. Proceedings of the National Academy

of Sciences USA 106: 1737–1742.

Moon, S., J.L. Siqueira-Neto, C.B. Moraes, G. Yang, M. Kang, L.H.

Freitas-Junior, and M.A. Hansen. 2014. An image-based algo-

rithm for precise and accurate high throughput assessment of

drug activity against the human parasite Trypanosoma cruzi.

PLoS ONE 9: e87188.

Moraski, G.C., L.D. Markley, P.A. Hipskind, H. Boshoff, S. Cho,

S.G. Franzblau, and M.J. Miller. 2011. Advent of imidazo[1,2-

a]pyridine-3-carboxamides with potent multi- and extended drug

resistant antituberculosis activity. ACS Medicinal Chemistry

Letters 2: 466–470.

Murima, P., J.D. McKinney, and K. Pethe. 2014. Targeting bacterial

central metabolism for drug development. Chemistry & Biology

21: 1423–1432.

Nichols, D., N. Cahoon, E.M. Trakhtenberg, L. Pham, A. Mehta, A.

Belanger,T. Kanigan, K. Lewis,and S.S. Epstein.2010. Use of ichip

for high-throughput in situ cultivation of ‘‘uncultivable’’ microbial

species. Applied and Environment Microbiology 76: 2445–2450.

Osorio, Y., B.L. Travi, A.R. Renslo, A.G. Peniche, and P.C. Melby.

2011. Identiﬁcation of small molecule lead compounds for

visceral leishmaniasis using a novel ex vivo splenic explant

model system. PLOS Neglected Tropical Diseases 5: e962.

Payne, D.J., M.N. Gwynn, D.J. Holmes, and D.L. Pompliano. 2007.

Drugs for bad bugs: Confronting the challenges of antibacterial

discovery. Nature Reviews Drug Discovery 6: 29–40.

Peng, B., Y.B. Su, H. Li, Y. Han, C. Guo, Y.M. Tian, and X.X. Peng.

2015. Exogenous alanine and/or glucose plus kanamycin kills

antibiotic-resistant bacteria. Cell Metabolism 21: 249–261.

Peniche, A.G., Y. Osorio, A.R. Renslo, D.E. Frantz, P.C. Melby, and

B.L. Travi. 2014. Development of an ex vivo lymph node

explant model for identiﬁcation of novel molecules active

against Leishmania major. Antimicrobial Agents and Che-

motherapy 58: 78–87.

Pethe, K., P. Bifani, J. Jang, S. Kang, S. Park, S. Ahn, J. Jiricek, J.

Jung, H.K. Jeon, J. Cechetto, T. Christophe, H. Lee, M. Kempf,

M. Jackson, A.J. Lenaerts, H. Pham, V. Jones, M.J. Seo, Y.M.

Kim, M. Seo, J.J. Seo, D. Park, Y. Ko, I. Choi, R. Kim, S.Y.

Kim, S. Lim, S.A. Yim, J. Nam, H. Kang, H. Kwon, C.T. Oh, Y.

Cho, Y. Jang, J. Kim, A. Chua, B.H. Tan, M.B. Nanjundappa,

S.P. Rao, W.S. Barnes, R. Wintjens, J.R. Walker, S. Alonso, S.

Lee, S. Oh, T. Oh, U. Nehrbass, S.J. Han, Z. No, J. Lee, P.

Brodin, S.N. Cho, and K. Nam. 2013. Discovery of Q203, a

potent clinical candidate for the treatment of tuberculosis.

Nature Medicine 19: 1157–1160.

Pethe, K., P.C. Sequeira, S. Agarwalla, K. Rhee, K. Kuhen, W.Y.

Phong, V. Patel, D. Beer, J.R. Walker, J. Duraiswamy, J. Jiricek,

T.H. Keller, A. Chatterjee, M.P. Tan, M. Ujjini, S.P. Rao, L.

Camacho, P. Bifani, P.A. Mak, I. Ma, S.W. Barnes, Z. Chen, D.

Plouffe, P. Thayalan, S.H. Ng, M. Au, B.H. Lee, B.H. Tan, S.

Ravindran, M. Nanjundappa, X. Lin, A. Goh, S.B. Lakshmi-

narayana, C. Shoen, M. Cynamon, B. Kreiswirth, V. Dartois,

E.C. Peters, R. Glynne, S. Brenner, and T. Dick. 2010. A

chemical genetic screen in Mycobacterium tuberculosis identi-

ﬁes carbon-source-dependent growth inhibitors devoid of in vivo

efﬁcacy. Nature Communications 1: 57.

Plouffe, D., A. Brinker, C. McNamara, K. Henson, N. Kato, K.

Kuhen, A. Nagle, F. Adria

´n, J.T. Matzen, P. Anderson, T.G.

Nam, N.S. Gray, A. Chatterjee, J. Janes, S.F. Yan, R. Trager, J.S.

Caldwell, P.G. Schultz, Y. Zhou, and E.A. Winzeler. 2008. In

silico activity proﬁling reveals the mechanism of action of

antimalarials discovered in a high-throughput screen. Proceed-

ings of the National Academy of Sciences USA 105: 9059–9064.

Ramachandran, S., P.S. Hameed, A. Srivastava, G. Shanbhag, S.

Morayya, N. Rautela, D. Awasthy, S. Kavanagh, S. Bharath, J.

A. L. T. Michelle et al.

123

Reddy, V. Panduga, K.R. Prabhakar, R. Saralaya, R. Nanduri, A.

Raichurkar, S. Menasinakai, V. Achar, M.B. Jimenez-Diaz, M.S.

Martinez, I. Angulo-Barturen, S. Ferrer, L.M. Sanz, F.J. Gamo,

S. Duffy, V.M. Avery, D. Waterson, M.C. Lee, O. Coburn-

Flynn, D.A. Fidock, P.S. Iyer, S. Narayanan, V. Hosagrahara,

and V.K. Sambandamurthy. 2014. N-aryl-2-aminobenzimida-

zoles: Novel, efﬁcacious, antimalarial lead compounds. Journal

of Medicinal Chemistry 57: 6642–6652.

Rao, M., T.L. Streur, F.E. Aldwell, and G.M. Cook. 2001. Intracel-

lular pH regulation by Mycobacterium smegmatis and Mycobac-

terium bovis BCG. Microbiology 147: 1017–1024.

Rao, S.P., S. Alonso, L. Rand, T. Dick, and K. Pethe. 2008. The

protonmotive force is required for maintaining ATP homeostasis

and viability of hypoxic, nonreplicating Mycobacterium tuber-

culosis.Proceedings of the National Academy of Sciences USA

105: 11945–11950.

Rao, S.P., S.B. Lakshminarayana, R.R. Kondreddi, M. Herve, L.R.

Camacho, P. Bifani, S.K. Kalapala, J. Jiricek, N.L. Ma, B.H.

Tan, S.H. Ng, M. Nanjundappa, S. Ravindran, P.G. Seah, P.

Thayalan, S.H. Lim, B.H. Lee, A. Goh, W.S. Barnes, Z. Chen, K.

Gagaring, A.K. Chatterjee, K. Pethe, K. Kuhen, J. Walker, G.

Feng, S. Babu, L. Zhang, F. Blasco, D. Beer, M. Weaver, V.

Dartois, R. Glynne, T. Dick, P.W. Smith, T.T. Diagana, and U.H.

Manjunatha. 2013. Indolcarboxamide is a preclinical candidate

for treating multidrug-resistant tuberculosis. Science Transla-

tional Medicine 5: 214ra168.

Reguera, R.M., E. Calvo-A

´lvarez, R. Alvarez-Velilla, and R. Balan

˜a-

Fouce. 2014. Target-based vs. phenotypic screenings in Leish-

mania drug discovery: A marriage of convenience or a dialogue

of the deaf? International Journal for Parasitology: Drugs and

Drug Resistance 4: 355–357.

Rice, L.B. 2008. Federal funding for the study of antimicrobial

resistance in nosocomial pathogens: No ESKAPE. Journal of

Infectious Diseases 197: 1079–1081.

Rice, L.B. 2010. Progress and challenges in implementing the

research on ESKAPE pathogens. Infection Control and Hospital

Epidemiology 31(Suppl 1): S7–S10.

Rodriguez, A., and R.L. Tarleton. 2012. Transgenic parasites

accelerate drug discovery. Trends in Parasitology 28: 90–92.

Rohde, K.H., D.F. Veiga, S. Caldwell, G. Balazsi, and D.G. Russell.

2012. Linking the transcriptional proﬁles and the physiological

states of Mycobacterium tuberculosis during an extended

intracellular infection. PLoS Pathogens 8: e1002769.

Rottmann,M., C. McNamara, B.K. Yeung, M.C.Lee, B. Zou, B. Russell,

P. Seitz, D.M. Plouffe, N.V. Dharia, J. Tan, S.B. Cohen, K.R.

Spencer, G.E. Gonzalez-Paez, S.B. Lakshminarayana, A. Goh, R.

Suwanarusk, T. Jegla, E.K. Schmitt, H.P. Beck, R. Brun, F. Nosten,

L. Renia, V. Dartois, T.H. Keller, D.A. Fidock, E.A. Winzeler, and

T.T. Diagana. 2010. Spiroindolones, a potent compound class for

the treatment of malaria. Science 329: 1175–1180.

Rybniker, J., J.M. Chen, C. Sala, R.C. Hartkoorn, A. Vocat, A.

Benjak, S. Boy-Rottger, M. Zhang, R. Szekely, Z. Greff, L. Orﬁ,

I. Szabadkai, J. Pato, G. Keri, and S.T. Cole. 2014. Anticytolytic

screen identiﬁes inhibitors of mycobacterial virulence protein

secretion. Cell Host & Microbe 16: 538–548.

Rybniker, J., A. Vocat, C. Sala, P. Busso, F. Pojer, A. Benjak, and

S.T. Cole. 2015. Lansoprazole is an antituberculous prodrug

targeting cytochrome bc1. Nature Communications 6: 7659.

Sams-Dodd, F. 2005. Target-based drug discovery: Is something

wrong? Drug Discovery Today 10: 139–147.

Sanz, L.M., M.B. Jimenez-Diaz, B. Crespo, C. De-Cozar, M.J.

Almela, I. Angulo-Barturen, P. Castaneda, J. Ibanez, E.P.

Fernandez, S. Ferrer, E. Herreros, S. Lozano, M.S. Martinez,

L. Rueda, J.N. Burrows, J.F. Garcia-Bustos, and F.J. Gamo.

2011. Cyclopropyl carboxamides, a chemically novel class of

antimalarial agents identiﬁed in a phenotypic screen. Antimicro-

bial Agents and Chemotherapy 55: 5740–5745.

Scharf, C., S. Riethdorf, H. Ernst, S. Engelmann, U. Volker, and M.

Hecker. 1998. Thioredoxin is an essential protein induced by

multiple stresses in Bacillus subtilis.Journal of Bacteriology

180: 1869–1877.

Singh, R., U. Manjunatha, H.I. Boshoff, Y.H. Ha, P. Niyomrattanakit,

R. Ledwidge, C.S. Dowd, I.Y. Lee, P. Kim, L. Zhang, S. Kang,

T.H. Keller, J. Jiricek, and C.E. Barry 3rd. 2008. PA-824 kills

nonreplicating Mycobacterium tuberculosis by intracellular NO

release. Science 322: 1392–1395.

Siqueira-Neto, J.L., S. Moon, J. Jang, G. Yang, C. Lee, H.K. Moon, E.

Chatelain, A. Genovesio, J. Cechetto, and L.H. Freitas-Junior.

2012. An image-based high-content screening assay for com-

pounds targeting intracellular Leishmania donovani amastigotes in

human macrophages. PLOS Neglected Tropical Diseases 6: e1671.

Smilkstein, M., N. Sriwilaijaroen, J.X. Kelly, P. Wilairat, and M.

Riscoe. 2004. Simple and inexpensive ﬂuorescence-based tech-

nique for high-throughput antimalarial drug screening. Antimi-

crobial Agents and Chemotherapy 48: 1803–1806.

Spillman, N.J., R.J. Allen, C.W. McNamara, B.K. Yeung, E.A.

Winzeler, T.T. Diagana, and K. Kirk. 2013. Na(?) regulation in

the malaria parasite Plasmodium falciparum involves the cation

ATPase PfATP4 and is a target of the spiroindolone antimalar-

ials. Cell Host & Microbe 13: 227–237.

Stanley, S.A., A.K. Barczak, M.R. Silvis, S.S. Luo, K. Sogi, M.

Vokes, M.A. Bray, A.E. Carpenter, C.B. Moore, N. Siddiqi, E.J.

Rubin, and D.T. Hung. 2014. Identiﬁcation of host-targeted

small molecules that restrict intracellular Mycobacterium tuber-

culosis growth. PLoS Pathogens 10: e1003946.

Stover, C.K., P. Warrener, D.R. VanDevanter, D.R. Sherman, T.M.

Arain, M.H. Langhorne, S.W. Anderson, J.A. Towell, Y. Yuan,

D.N. McMurray, B.N. Kreiswirth, C.E. Barry, and W.R. Baker.

2000. A small-molecule nitroimidazopyran drug candidate for

the treatment of tuberculosis. Nature 405: 962–966.

Sundaramurthy, V., R. Barsacchi, N. Samusik, G. Marsico, J.

Gilleron, I. Kalaidzidis, F. Meyenhofer, M. Bickle, Y. Kalaidzi-

dis, and M. Zerial. 2013. Integration of chemical and RNAi

multiparametric proﬁles identiﬁes triggers of intracellular

mycobacterial killing. Cell Host & Microbe 13: 129–142.

Swaim, L.E., L.E. Connolly, H.E. Volkman, O. Humbert, D.E. Born,

and L. Ramakrishnan. 2006. Mycobacterium marinum infection

of adult zebraﬁsh causes caseating granulomatous tuberculosis

and is moderated by adaptive immunity. Infection and Immunity

74: 6108–6117.

Swinney, D.C. 2013. Phenotypic vs. target-based drug discovery for

ﬁrst-in-class medicines. Clinical Pharmacology and Therapeu-

tics 93: 299–301.

Sykes, M.L., and V.M. Avery. 2009a. Development of an alamar blue

viability assay in 384-well format for high throughput whole cell

screening of Trypanosoma brucei brucei bloodstream form strain

427. American Journal of Tropical Medicine and Hygeine 81:

665–674.

Sykes, M.L., and V.M. Avery. 2009b. A luciferase based viability

assay for ATP detection in 384-well format for high throughput

whole cell screening of Trypanosoma brucei brucei bloodstream

form strain 427. Parasit Vectors 2: 54.

Sykes, M.L., J.B. Baell, M. Kaiser, E. Chatelain, S.R. Moawad, D.

Ganame, J.R. Ioset, and V.M. Avery. 2012. Identiﬁcation of

compounds with anti-proliferative activity against Trypanosoma

brucei brucei strain 427 by a whole cell viability based HTS

campaign. PLOS Neglected Tropical Diseases 6: e1896.

Takaki, K., C.L. Cosma, M.A. Troll, and L. Ramakrishnan. 2012. An

in vivo platform for rapid high-throughput antitubercular drug

discovery. Cell Reports 2: 175–184.

Next-generation antimicrobials: from chemical biology to ﬁrst-in-class drugs

123

Takaki, K., J.M. Davis, K. Winglee, and L. Ramakrishnan. 2013.

Evaluation of the pathogenesis and treatment of Mycobacterium

marinum infection in zebraﬁsh. Nature Protocols 8: 1114–1124.

Takayama, K., H.K. Schnoes, E.L. Armstrong, and R.W. Boyle. 1975.

Site of inhibitory action of isoniazid in the synthesis of mycolic

acids in Mycobacterium tuberculosis.Journal of Lipid Research

16: 308–317.

Tasneen, R., K. Williams, O. Amoabeng, A. Minkowski, K.E. Mdluli,

A.M. Upton, and E.L. Nuermberger. 2015. Contribution of the

nitroimidazoles PA-824 and TBA-354 to the activity of novel

regimens in murine models of tuberculosis. Antimicrobial Agents

and Chemotherapy 59: 129–135.

Terstappen, G.C., C. Schlupen, R. Raggiaschi, and G. Gaviraghi.

2007. Target deconvolution strategies in drug discovery. Nature

Reviews Drug Discovery 6: 891–903.

Tun, K.M., M. Imwong, K.M. Lwin, A.A. Win, T.M. Hlaing, T.

Hlaing, K. Lin, M.P. Kyaw, K. Plewes, M.A. Faiz, M. Dhorda,

P.Y. Cheah, S. Pukrittayakamee, E.A. Ashley, T.J. Anderson, S.

Nair, M. McDew-White, J.A. Flegg, E.P. Grist, P. Guerin, R.J.

Maude, F. Smithuis, A.M. Dondorp, N.P. Day, F. Nosten, N.J.

White, and C.J. Woodrow. 2015. Spread of artemisinin-resistant

Plasmodium falciparum in Myanmar: a cross-sectional survey of

the K13 molecular marker. The Lancet Infectious Diseases 15:

415–421.

Uziel, O., I. Borovok, R. Schreiber, G. Cohen, and Y. Aharonowitz.

2004. Transcriptional regulation of the Staphylococcus aureus

thioredoxin and thioredoxin reductase genes in response to oxygen

and disulﬁde stress. Journal of Bacteriology 186: 326–334.

Vaidya, A.B., J.M. Morrisey, Z. Zhang, S. Das, T.M. Daly, T.D. Otto,

N.J. Spillman, M. Wyvratt, P. Siegl, J. Marfurt, G. Wirjanata,

B.F. Sebayang, R.N. Price, A. Chatterjee, A. Nagle, M. Stasiak,

S.A. Charman, I. Angulo-Barturen, S. Ferrer, M. Belen Jimenez-

Diaz, M.S. Martinez, F.J. Gamo, V.M. Avery, A. Ruecker, M.

Delves, K. Kirk, M. Berriman, S. Kortagere, J. Burrows, E. Fan,

and L.W. Bergman. 2014. Pyrazoleamide compounds are potent

antimalarials that target Na ?homeostasis in intraerythrocytic

Plasmodium falciparum.Nat Commun 5: 5521.

Vander Heiden, M.G. 2011. Targeting cancer metabolism: A

therapeutic window opens. Nature Reviews Drug Discovery

10: 671–684.

VanderVen, B.C., R.J. Fahey, W. Lee, Y. Liu, R.B. Abramovitch, C.

Memmott, A.M. Crowe, L.D. Eltis, E. Perola, D.D. Deininger, T.

Wang, C.P. Locher, and D.G. Russell. 2015. Novel inhibitors of

cholesterol degradation in Mycobacterium tuberculosis reveal

how the bacterium’s metabolism is constrained by the intracel-

lular environment. PLoS Pathogens 11: e1004679.

Viotti, R., C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M.G.

Alvarez, M. Postan, and A. Armenti. 2006. Long-term cardiac

outcomes of treating chronic Chagas disease with benznidazole

versus no treatment: A nonrandomized trial. Annals of Internal

Medicine 144: 724–734.

Voorberg-van der Wel, A., A.M. Zeeman, S.M. van Amsterdam, A.

van den Berg, E.J. Klooster, S. Iwanaga, C.J. Janse, G.J. van

Gemert, R. Sauerwein, N. Beenhakker, G. Koopman, A.W.

Thomas, and C.H. Kocken. 2013. Transgenic ﬂuorescent Plas-

modium cynomolgi liver stages enable live imaging and puriﬁ-

cation of Malaria hypnozoite-forms. PLoS ONE 8: e54888.

Vossen, M.G., S. Pferschy, P. Chiba, and H. Noedl. 2010. The SYBR

Green I malaria drug sensitivity assay: performance in low

parasitemia samples. American Journal of Tropical Medicine

and Hygeine 82: 398–401.

Wakamoto, Y., N. Dhar, R. Chait, K. Schneider, F. Signorino-Gelo, S.

Leibler, and J.D. McKinney. 2013. Dynamic persistence of

antibiotic-stressed mycobacteria. Science 339: 91–95.

Wells, T.N., J.N. Burrows, and J.K. Baird. 2010. Targeting the

hypnozoite reservoir of Plasmodium vivax: the hidden obstacle

to malaria elimination. Trends in Parasitology 26: 145–151.

White, N.J., S. Pukrittayakamee, A.P. Phyo, R. Rueangweerayut, F.

Nosten, P. Jittamala, A. Jeeyapant, J.P. Jain, G. Lefevre, R. Li,

B. Magnusson, T.T. Diagana, and F.J. Leong. 2014. Spiroin-

dolone KAE609 for falciparum and vivax malaria. New England

Journal of Medicine 371: 403–410.

WHO (2013) WHO Global Tuberculosis Report 2013. World Health

Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland,

p. 306.

Wongsrichanalai, C., and S.R. Meshnick. 2008. Declining artesunate-

meﬂoquine efﬁcacy against falciparum malaria on the Cambo-

dia-Thailand border. Emerging Infectious Diseases 14: 716–719.

Yeung, B.K., B. Zou, M. Rottmann, S.B. Lakshminarayana, S.H.

Ang, S.Y. Leong, J. Tan, J. Wong, S. Keller-Maerki, C. Fischli,

A. Goh, E.K. Schmitt, P. Krastel, E. Francotte, K. Kuhen, D.

Plouffe, K. Henson, T. Wagner, E.A. Winzeler, F. Petersen, R.

Brun, V. Dartois, T.T. Diagana, and T.H. Keller. 2010.

Spirotetrahydro beta-carbolines (spiroindolones): A new class

of potent and orally efﬁcacious compounds for the treatment of

malaria. Journal of Medicinal Chemistry 53: 5155–5164.

Zlitni, S., L.F. Ferruccio, and E.D. Brown. 2013. Metabolic suppres-

sion identiﬁes new antibacterial inhibitors under nutrient limi-

tation. Nature Chemical Biology 9: 796–804.

Zou, B., A. Nagle, A.K. Chatterjee, S.Y. Leong, L.J. Tan, W.L. Sim,

P. Mishra, P. Guntapalli, D.C. Tully, S.B. Lakshminarayana,

C.S. Lim, Y.C. Tan, S.N. Abas, C. Bodenreider, K.L. Kuhen, K.

Gagaring, R. Borboa, J. Chang, C. Li, T. Hollenbeck, T.

Tuntland, A.M. Zeeman, C.H. Kocken, C. McNamara, N. Kato,

E.A. Winzeler, B.K. Yeung, T.T. Diagana, P.W. Smith, and J.

Roland. 2014. Lead optimization of imidazopyrazines: A new

class of antimalarial with activity on Plasmodium liver stages.

ACS Med Chem Lett 5: 947–950.

A. L. T. Michelle et al.

123

DXP Synthase Function in a Bacterial Metabolic Adaptation and Implications for Antibacterial Strategies

Article

Full-text available

Apr 2023

Pathogenic bacteria possess a remarkable ability to adapt to fluctuating host environments and cause infection. Disturbing bacterial central metabolism through inhibition of 1-deoxy-d-xylulose 5-phosphate synthase (DXPS) has the potential to hinder bacterial adaptation, representing a new antibacterial strategy. DXPS functions at a critical metabolic branchpoint to produce the metabolite DXP, a precursor to pyridoxal-5-phosphate (PLP), thiamin diphosphate (ThDP) and isoprenoids presumed essential for metabolic adaptation in nutrient-limited host environments. However, specific roles of DXPS in bacterial adaptations that rely on vitamins or isoprenoids have not been studied. Here we investigate DXPS function in an adaptation of uropathogenic E. coli (UPEC) to d-serine (d-Ser), a bacteriostatic host metabolite that is present at high concentrations in the urinary tract. UPEC adapt to d-Ser by producing a PLP-dependent deaminase, DsdA, that converts d-Ser to pyruvate, pointing to a role for DXPS-dependent PLP synthesis in this adaptation. Using a DXPS-selective probe, butyl acetylphosphonate (BAP), and leveraging the toxic effects of d-Ser, we reveal a link between DXPS activity and d-Ser catabolism. We find that UPEC are sensitized to d-Ser and produce sustained higher levels of DsdA to catabolize d-Ser in the presence of BAP. In addition, BAP activity in the presence of d-Ser is suppressed by β-alanine, the product of aspartate decarboxylase PanD targeted by d-Ser. This BAP-dependent sensitivity to d-Ser marks a metabolic vulnerability that can be exploited to design combination therapies. As a starting point, we show that combining inhibitors of DXPS and CoA biosynthesis displays synergy against UPEC grown in urine where there is increased dependence on the TCA cycle and gluconeogenesis from amino acids. Thus, this study provides the first evidence for a DXPS-dependent metabolic adaptation in a bacterial pathogen and demonstrates how this might be leveraged for development of antibacterial strategies against clinically relevant pathogens.

Development of concepts for the genomic mining of novel secondary metabolites in symbiotic cyanobacteria

Thesis

Jan 2020

Daniel Dehm

Naturstoffe sind seit der goldenen Ära der Antibiotika von immer größerem Interesse, sowohl für die Grundlagenforschung als auch die Angewandten Wissenschaften, da sie die Hauptquelle für neuartige Pharmazeutika mit starken antibiotischen, anti-entzündlichen und Antitumor-Aktivitäten darstellen. Neben den technologischen Fortschritten im Bereich der Hochdurchsatz Genomsequenzierung und dem verbesserten Verständnis des modularen Aufbaus der Biosynthesewege von Sekundärmetaboliten, kam es auch zu einem Wechsel vom labor-gestützten Screening aktiver Zellextrakte hin zum Algorithmen-basierten in silico Screening nach neuen Naturstoff-Biosyntheseclustern. Obwohl die steigende Zahl verfügbarer Genomsequenzen zeigte, dass nicht-ribosomale Peptid-Synthetasen (NRPS), Polyketid-Synthasen (PKS), und ribosomal synthetisierte und posttranslational modifizierte Peptide (RiPPs) ubiquitär in allen Sparten des Lebens gefunden werden können, so zeigen einige Phyla wie Actinobakterien oder Cyanobakterien eine besonders hohe Dichte an Sekundärmetabolitclustern. Der fakultativ symbiotische, N2-fixierende Modellorganismus N. punctiforme PCC73102 ist ein terrestrisches typ-IV Cyanobakterium, welches nicht nur einen besonders hohen Anteil seines Genoms der Produktion von Sekundärmetaboliten widmet, sondern zusätzlich noch genetisch modifizierbar ist. Eine AntiSMASH Analyse des Genoms zeigte, dass N. punctiforme insgesamt sechzehn potentielle Sekundärmetabolitcluster besitzt, von denen aber bis heute nur zweien ein spezifisches Produkt zugewiesen werden konnte. Das macht N. punctiforme zu einem perfekten Testorganismus für die Entwicklung eines neuartigen kombinatorischen Genomic Mining Ansatzes zur Detektion von bislang unbeschriebenen Naturstoffen. Der neuartige Ansatz, der im Rahmen dieser Studie entwickelt wurde, stellt eine Kombination aus Genomic Mining, unabhängigen Monitoring-Techniken sowie modifizierten Kultivierungsbedingungen dar und führte nicht nur zu neuen Erkenntnissen im Bereich cyanobakterieller Naturstoffsynthese, sondern letztlich auch zur Entdeckung eines neuen, von N. punctiforme produzierten, Naturstoffs. Die Herstellung und Untersuchung einer Reporterstamm Bibliothek, bestehend aus je einem CFP-produzierenden Transkriptionsreporter für jedes der sechzehn Sekundärmetabolitcluster von N. punctiforme, zeigte, dass im Gegensatz zur Erwartung nicht alle Biosynthesecluster für die man kein Produkt nachweisen kann auch nicht exprimiert werden. Stattdessen konnten klar definierbare Expressionsmuster beschrieben werden, was deutlich machte, dass die Naturstoffproduktion einer engen Regulation unterliegt und nur ein kleiner Teil der Biosynthesecluster unter Standardbedingungen tatsächlich still sind. Darüber hinaus führte die Erhöhung der Lichtintensität sowie der Kohlenstoffdioxid-Verfügbarkeit zusammen mit der Kultivierung von N. punctiforme zu extrem hohen Zelldichten zu einer starken Erhöhung der gesamten metabolischen Aktivität des Organismus. Nähere Untersuchungen der Zellextrakte dieser hoch-dichte Kultivierungen führten letztlich zur Entdeckung einer neuartigen Gruppe von Microviridinen mit verlängerter Peptidsequenz, welche Microviridin N3-N9 genannt wurden. Sowohl die Kultivierung der Transkriptionsreporter als auch die RTqPCR-basierte Untersuchung der Transkriptionslevel der verschiedenen Biosynthesecluster zeigten, dass die hoch-Zelldichte Kultivierung von N. punctiforme zu einer Aktivierung von 50% der vorhandenen Sekundärmetabolitcluster führt. Im Gegensatz zu dieser sehr breit-gefächerten Aktivierung, führt die Co-Kultivierung von N. punctiforme in chemischen oder physischen Kontakt zu einer N-gehungerten Wirtspflanze (Blasia pusilla) zu einer sehr spezifischen Aktivierung der RIPP4 und RiPP3 Biosynthesecluster. Obwohl dieser Effekt mittels verschiedener unabhängiger Methoden bestätigt werden konnte und trotz intensiver Analysebemühungen, konnte jedoch keinem der beiden Cluster ein Produkt zugeordnet werden. Diese Studie stellt die erste weitreichende, systematische Analyse eines cyanobakteriellen Sekundärmetaboloms durch einen kombinatorischen Ansatz aus Genomic Mining und unabhängigen Monitoring-Techniken dar und kann als neue strategische Herangehensweise für die Untersuchung anderer Organismen hinsichtlich ihrer Sekundärmetabolit-Produktion dienen. Obwohl es bereits gut beschriebene einzelne Sekundärmetabolite gibt, wie beispielweise den Zelldifferenzierungsfaktor PatS in Anabaena sp. PCC7120, so ist der Grad an Regulation der in dieser Studie gezeigt werden konnte bislang beispiellos und die Entschlüsselung dieser Mechanismen könnte die Entdeckung neuer Naturstoffe stark beschleunigen. Daneben lassen die Ergebnisse aber auch darauf schließen, dass die Induktion der Biosynthesewege nicht das eigentliche Problem darstellt, sondern vielmehr die verlässliche Detektion deren Produkte. Die Erarbeitung neuer Analytik-Strategien könnte somit auch einen deutlichen Einfluss auf die Geschwindigkeit der Entdeckung neuer Naturstoffe haben.

Hypothesis-generating Proteome Perturbation to Identify NEU-4438 and Acoziborole Modes of Action in the African Trypanosome

Article

Full-text available

Oct 2022

NEU-4438 is a lead for development of drugs against Trypanosoma brucei, that causes human African trypanosomiasis. Optimized with phenotypic screening, targets of NEU-4438 are unknown. Herein, we present a cell perturbome workflow that compares NEU-4438’s molecular modes of action to those of SCYX-7158 (acoziborole). Following a 6 h perturbation of trypanosomes, NEU-4438 and acoziborole reduced steady-state amounts of 68 and 92 unique proteins, respectively. After analysis of proteomes, hypotheses formulated for modes of action were tested: Acoziborole and NEU-4438 have different modes of action. Whereas NEU-4438 prevented DNA biosynthesis and basal body maturation, acoziborole destabilized CPSF3 and other proteins, inhibited polypeptide translation, and reduced endocytosis of haptoglobin-hemoglobin. These data point to CPSF3-independent modes of action for acoziborole. In case of polypharmacology, the cell-perturbome workflow elucidates modes of action because it is target-agnostic. Finally, the workflow can be used in any cell that is amenable for proteomic and molecular biology experiments.

Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase

Article

Full-text available

Sep 2018

The impact of multi-drug resistant bacterial strains on human health is reaching worrisome levels. Over 2 million people are infected by resistant bacteria, and more than 700,000 people die each year because of the continuous spread of resistant strains. The development of new antibiotics and the prudent use of existing ones to prolong their lifespan require a constant effort by drug industries and healthcare workers. The re-purposing of existing drugs for use as antimicrobial agents would streamline the development of new antibacterial strategies. As part of this effort, we screened a panel of drugs previously characterized to be epigenetic modulators/pro-apoptotic/differentiative drugs. We selected a few compounds that alter Gram-positive growth. Among these, UVI5008, a derivative of the natural compound psammaplin A (Psa_A), was identified. The interaction of Psa_A with the DNA gyrase enzyme has been shown, and here, we hypothesized and confirmed the gyrase-specific activity by biochemical assays. UVI5008 exhibited growth inhibition activity against Staphylococcus aureus via structural modification of the cell wall, which was observed by SEM electron microscopy. Based on our findings, we propose UVI5008 as an alternative antibacterial compound against methicillin-resistant (Met.R) S. aureus strains.

Application of Bioassay-Guided Fractionation Coupled with a Molecular Approach for the Dereplication of Antimicrobial Metabolites

Article

Full-text available

Dec 2016
CHROMATOGRAPHIA

A systematically delineated dereplication approach was described based on genome mining and bioassay-guided fractionation using endophytic fungus Xylaria psidii FPL-52(S) isolated from leaves of Ficus pumila Linn., (Moraceae). A polyketide synthase gene-based molecular screening strategy by a degenerate oligonucleotide primer polymerase chain reaction technique coupled with a bioinformatic phylogenomic approach revealed the presence of an iterative polyketide synthase gene within the genome of Xylaria psidii FPL-52(S). Chemical dereplication of ethyl acetate extract derived from a submerged fermentation culture broth of Xylaria psidii FPL-52(S) by bioassay-guided chromatographic and hyphenated analytical spectroscopic techniques led to the identification of polyketide mycoalexin 3-O-methylmellein. Antimicrobial profiling and minimal inhibitory concentration values for 3-O-methylmellein were determined by disc diffusion and microbroth dilution techniques. Gram-positive bacteria, dermatophytic and phytopathogenic fungi were susceptible in terms of inhibition zone and minimum inhibitory concentration values when compared to co-assayed standards. Herein, we highlight and demonstrate an improved approach which facilitates efficient dereplication and effect-guided fractionation of antimicrobial metabolite(s). The present work flow serves as a promising dereplication tool to survey the biosynthetic potential of endophytic fungal diversity, thereby identifying the most promising strains and prioritizing them for novel polyketide-derived antimicrobial metabolite discovery.

Natural product discovery: past, present, and future

Article

Full-text available

Jan 2016
J IND MICROBIOL BIOT

Microorganisms have provided abundant sources of natural products which have been developed as commercial products for human medicine, animal health, and plant crop protection. In the early years of natural product discovery from microorganisms (The Golden Age), new antibiotics were found with relative ease from low-throughput fermentation and whole cell screening methods. Later, molecular genetic and medicinal chemistry approaches were applied to modify and improve the activities of important chemical scaffolds, and more sophisticated screening methods were directed at target disease states. In the 1990s, the pharmaceutical industry moved to high-throughput screening of synthetic chemical libraries against many potential therapeutic targets, including new targets identified from the human genome sequencing project, largely to the exclusion of natural products, and discovery rates dropped dramatically. Nonetheless, natural products continued to provide key scaffolds for drug development. In the current millennium, it was discovered from genome sequencing that microbes with large genomes have the capacity to produce about ten times as many secondary metabolites as was previously recognized. Indeed, the most gifted actinomycetes have the capacity to produce around 30-50 secondary metabolites. With the precipitous drop in cost for genome sequencing, it is now feasible to sequence thousands of actinomycete genomes to identify the "biosynthetic dark matter" as sources for the discovery of new and novel secondary metabolites. Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.

Potent Inhibition of E. coli DXP Synthase by a gem-Diaryl Bisubstrate Analog

Article

Mar 2024

New antimicrobial strategies are needed to address pathogen resistance to currently used antibiotics. Bacterial central metabolism is a promising target space for the development of agents that selectively target bacterial pathogens. 1-Deoxy-d-xylulose 5-phosphate synthase (DXPS) converts pyruvate and d-glyceraldehyde 3-phosphate (d-GAP) to DXP, which is required for synthesis of essential vitamins and isoprenoids in bacterial pathogens. Thus, DXPS is a promising antimicrobial target. Toward this goal, our lab has demonstrated selective inhibition of Escherichia coli DXPS by alkyl acetylphosphonate (alkylAP)-based bisubstrate analogs that exploit the requirement for ternary complex formation in the DXPS mechanism. Here, we present the first DXPS structure with a bisubstrate analog bound in the active site. Insights gained from this cocrystal structure guided structure–activity relationship studies of the bisubstrate scaffold. A low nanomolar inhibitor (compound 8) bearing a gem-dibenzyl glycine moiety conjugated to the acetylphosphonate pyruvate mimic via a triazole-based linker emerged from this study. Compound 8 was found to exhibit slow, tight-binding inhibition, with contacts to E. coli DXPS residues R99 and R478 demonstrated to be important for this behavior. This work has discovered the most potent DXPS inhibitor to date and highlights a new role of R99 that can be exploited in future inhibitor designs toward the development of a novel class of antimicrobial agents.

Structural approaches to pathway specific antimicrobial agents

Article

Feb 2020
TRANSL RES

This perspective provides an overview of the evolution of antibiotic discovery from a largely phenotypic-based effort, through an intensive structure-based design focus, to a more holistic approach today. The current focus on antibiotic development incorporates assay and discovery conditions that replicate the host environment as much as feasible. They also incorporate several strategies, including target identification and validation within the whole cell environment, a variety of target deconvolution methods, and continued refinement of structure-based design approaches.

Chemical genetics-based development of small molecules targeting hepatitis C virus

Article

Aug 2017

Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today’s advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or telaprevir. In the past several years, various novel small molecules have been discovered and some of them (i.e., HCV polymerase, protease, helicase and entry inhibitors) have undergone clinical trials. Between 2013 and 2016, the second-generation DAA drugs simeprevir, asunaprevir, daclatasvir, dasabuvir, sofosbuvir, and elbasvir were approved, as well as the combinational drugs Harvoni®, Zepatier®, Technivie®, and Epclusa®. A number of reviews have been recently published describing the structure–activity relationship (SAR) in the development of HCV inhibitors and outlining current therapeutic approaches to hepatitis C infection. Target identification involves studying a drug’s mechanism of action (MOA), and a variety of target identification methods have been developed in the past few years. Chemical biology has emerged as a powerful tool for studying biological processes using small molecules. The use of chemical genetic methods is a valuable strategy for studying the molecular mechanisms of the viral lifecycle and screening for anti-viral agents. Two general screening approaches have been employed: forward and reverse chemical genetics. This review reveals information on the small molecules in HCV drug discovery by using chemical genetics for targeting the HCV protein and describes successful examples of targets identified with these methods.

Lansoprazole is an antituberculous prodrug targeting cytochrome bc1

Article

Full-text available

Jul 2015

Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in a host cell-based assay, we show that the blockbuster drug lansoprazole (Prevacid), a gastric proton-pump inhibitor, has intracellular activity against M. tuberculosis. Ex vivo pharmacokinetics and target identification studies reveal that lansoprazole kills M. tuberculosis by targeting its cytochrome bc1 complex through intracellular sulfoxide reduction to lansoprazole sulfide. This novel class of cytochrome bc1 inhibitors is highly active against drug-resistant clinical isolates and spares the human H(+)K(+)-ATPase thus providing excellent opportunities for targeting the major pathogen M. tuberculosis. Our finding provides proof of concept for hit expansion by metabolic activation, a powerful tool for antibiotic screens.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Article

Full-text available

Jun 2015
NATURE

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

Article

Full-text available

Apr 2015

Significance The identification of new antibiotics with novel mechanisms of action has become a pressing need considering the growing threat of drug-resistant infections. We have identified auranofin, an FDA-approved drug, as having potent bactericidal activity against Gram-positive pathogenic bacteria. Auranofin inhibits an enzyme, thioredoxin reductase, not targeted by other antibiotics, and thus retains efficacy against many clinically relevant drug-resistant strains, including in a mouse model of infection. Because auranofin is an approved drug, its route to the clinic may be expedited with reduced cost. Our work suggests that auranofin is a candidate for drug repurposing in antibacterial therapy.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Article

Full-text available

Mar 2015
LANCET

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks of treatment. We did this phase 2b study of bactericidal activity-defined as the decrease in colony forming units (CFUs) of Mycobacterium tuberculosis in the sputum of patients with microscopy smear-positive pulmonary tuberculosis-at eight sites in South Africa and Tanzania. We enrolled treatment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by computer-generated sequences to receive either 8 weeks of moxifloxacin, 100 mg pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current standard care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen). A group of patients with MDR tuberculosis received MPa200Z (DRMPa200Z group). The primary outcome was bactericidal activity measured by the mean daily rate of reduction in M tuberculosis CFUs per mL overnight sputum collected once a week, with joint Bayesian non-linear mixed-effects regression modelling. We also assessed safety and tolerability by monitoring adverse events. This study is registered with ClinicalTrials.gov, number NCT01498419. Between March 24, 2012, and July 26, 2013 we enrolled 207 patients and randomly assigned them to treatment groups; we assigned 60 patients to the MPa100Z regimen, 62 to the MPa200Z regimen, and 59 to the HRZE regimen. We non-randomly assigned 26 patients with drug-resistant tuberculosis to the DRMPa200Z regimen. In patients with drug-susceptible tuberculosis, the bactericidal activity of MPa200Z (n=54) on days 0-56 (0·155, 95% Bayesian credibility interval 0·133-0·178) was significantly greater than for HRZE (n=54, 0·112, 0·093-0·131). DRMPa200Z (n=9) had bactericidal activity of 0·117 (0·070-0·174). The bactericidal activity on days 7-14 was strongly associated with bactericidal activity on days 7-56. Frequencies of adverse events were similar to standard treatment in all groups. The most common adverse event was hyperuricaemia in 59 (29%) patients (17 [28%] patients in MPa100Z group, 17 [27%] patients in MPa200Z group, 17 [29%] patients. in HRZE group, and 8 [31%] patients in DRMPa200Z group). Other common adverse events were nausea in (14 [23%] patients in MPa100Z group, 8 [13%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 4 [15%] patients in DRMPa200Z group). No on-treatment electrocardiogram occurrences of corrected QT interval more than 500 ms (an indicator of potential of ventricular tachyarrhythmia) were reported. No phenotypic resistance developed to any of the drugs in the regimen. The combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity in drug-susceptible tuberculosis during 8 weeks of treatment. Results were consistent between drug-susceptible and MDR tuberculosis. This new regimen is ready to enter phase 3 trials in patients with drug-susceptible tuberculosis and MDR-tuberculosis, with the goal of shortening and simplifying treatment. Global Alliance for TB Drug Development. Copyright © 2015 Elsevier Ltd. All rights reserved.

Triaminopyrimidine is a fast killing and long acting antimalarial clinical candidate

Article

Full-text available

May 2015

The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf. The clinical candidate (compound 12) is efficacious in a mouse model of Pf malaria with an ED99 <30 mg kg(-1) and displays good in vivo safety margins in guinea pigs and rats. With a predicted half-life of 36 h in humans, a single dose of 260 mg might be sufficient to maintain therapeutic blood concentration for 4-5 days. Whole-genome sequencing of resistant mutants implicates the vacuolar ATP synthase as a genetic determinant of resistance to TAPs. Our studies highlight the potential of TAPs for single-dose treatment of Pf malaria in combination with other agents in clinical development.

Spread of artemisinin-resistant Plasmodium falciparum inMyanmar: a cross-sectional survey of the K13 molecular Marker

Article

Full-text available

Feb 2015

Emergence of artemisinin resistance in southeast Asia poses a serious threat to the global control of Plasmodium falciparum malaria. Discovery of the K13 marker has transformed approaches to the monitoring of artemisinin resistance, allowing introduction of molecular surveillance in remote areas through analysis of DNA. We aimed to assess the spread of artemisinin-resistant P falciparum in Myanmar by determining the relative prevalence of P falciparum parasites carrying K13-propeller mutations. We did this cross-sectional survey at malaria treatment centres at 55 sites in ten administrative regions in Myanmar, and in relevant border regions in Thailand and Bangladesh, between January, 2013, and September, 2014. K13 sequences from P falciparum infections were obtained mainly by passive case detection. We entered data into two geostatistical models to produce predictive maps of the estimated prevalence of mutations of the K13 propeller region across Myanmar. Overall, 371 (39%) of 940 samples carried a K13-propeller mutation. We recorded 26 different mutations, including nine mutations not described previously in southeast Asia. In seven (70%) of the ten administrative regions of Myanmar, the combined K13-mutation prevalence was more than 20%. Geospatial mapping showed that the overall prevalence of K13 mutations exceeded 10% in much of the east and north of the country. In Homalin, Sagaing Region, 25 km from the Indian border, 21 (47%) of 45 parasite samples carried K13-propeller mutations. Artemisinin resistance extends across much of Myanmar. We recorded P falciparum parasites carrying K13-propeller mutations at high prevalence next to the northwestern border with India. Appropriate therapeutic regimens should be tested urgently and implemented comprehensively if spread of artemisinin resistance to other regions is to be avoided. Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme and the Bill & Melinda Gates Foundation. Copyright © 2015 Tun et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.

A new antibiotic kills pathogens without detectable resistance

Article